{"content":"<li class=\"n-box-item date-title\" data-end=\"1530158399\" data-start=\"1530072000\" data-txt=\"Monday, December 23, 2019\">Wednesday, June 27, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3366725\" data-ts=\"1530137700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366725-chipotle-to-take-115m-135m-charge-for-store-closings-in-restructure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle to take $115M-$135M charge for store closings in restructure</a></h4><ul>     <li>Chipotle Mexican Grill (NYSE:<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>)&nbsp;<font color='red'>-3.3%</font> after-hours on plans to <a href=\"https://www.reuters.com/article/us-chipotle-investor/chipotle-to-launch-new-loyalty-program-in-2019-idUSKBN1JN33S?il=0\" target=\"_blank\">take $115M-$135M in non-recurring charges</a>, including $50M-$60M in Q2, to shut down 55-65 underperforming restaurants and restructure the chain.</li>     <li>CMG held a conference call to discuss changes under its new management team, which included additions to its dining menu, a marketing push to raise awareness of mobile ordering, and the launch of a customer loyalty program next year, with testing of the program in H2 of this year.</li>          <li>CMG says about half of the store closures will occur in the next 30 days, while closures that involve more complicated lease buyouts will stretch longer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366725\" data-linked=\"Chipotle to take $115M-$135M charge for store closings in restructure\" data-tweet=\"$CMG - Chipotle to take $115M-$135M charge for store closings in restructure https://seekingalpha.com/news/3366725-chipotle-to-take-115m-135m-charge-for-store-closings-in-restructure?source=tweet\" data-url=\"https://seekingalpha.com/news/3366725-chipotle-to-take-115m-135m-charge-for-store-closings-in-restructure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366720\" data-ts=\"1530136051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIR\" target=\"_blank\">PIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366720-pier-1-plunges-15-q1-store-sales-fall-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pier 1 plunges 15% as Q1 same-store sales fall more than expected</a></h4><ul>     <li>Pier 1 Imports (NYSE:<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a>) <font color='red'>-15.3%</font> after-hours despite posting better than expected <a href=\"https://seekingalpha.com/news/3366678-pier-1-imports-beats-0_03-misses-revenue\" target=\"_blank\">Q1 earnings</a>, as same-store sales disappoint and Q2 earnings guidance comes in below consensus.</li>     <li>PIR says Q1 revenues fell 9% Y/Y to $372M, comparable store sales tumbled 8.2% Y/Y and below company  guidance for a 7%-8% decline, and gross profit fell to 32.3% of net sales from 37% in the same period a year ago.</li>     <li>PIR issues downside guidance for Q2, seeing an EPS loss of $0.54-$0.58 vs. analyst consensus estimate of a $0.21 loss, with comparable sales expected to decline 6%-7%; for FY 2019, PIR sees a loss of $0.17-$0.36 vs. consensus for a $0.31 loss, with comparable sales expected to rise 1.5%-2.5%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366720\" data-linked=\"Pier 1 plunges 15% as Q1 same-store sales fall more than expected\" data-tweet=\"$PIR - Pier 1 plunges 15% as Q1 same-store sales fall more than expected https://seekingalpha.com/news/3366720-pier-1-plunges-15-q1-store-sales-fall-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3366720-pier-1-plunges-15-q1-store-sales-fall-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366718\" data-ts=\"1530135250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HFWA\" target=\"_blank\">HFWA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366718-heritage-financialplus-2_4-on-move-to-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heritage Financial +2.4% on move to SmallCap 600</a></h4><ul>   <li>Heritage Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/HFWA' title='Heritage Financial Corporation'>HFWA</a>) is <font color='green'>up 2.4%</font> after hours on news that it's moving into the S&amp;P SmallCap 600.</li>    <li>It's replacing Kindred Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a>), set to be acquired by a group including Humana (already part of the S&amp;P 500).</li>    <li>The move is effective prior to Monday's open.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366718\" data-linked=\"Heritage Financial +2.4% on move to SmallCap 600\" data-tweet=\"$HFWA $HFWA $KND - Heritage Financial +2.4% on move to SmallCap 600 https://seekingalpha.com/news/3366718-heritage-financialplus-2_4-on-move-to-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3366718-heritage-financialplus-2_4-on-move-to-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366717\" data-ts=\"1530135102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PED\" target=\"_blank\">PED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366717-after-hours-gainers-losers-06-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (06/27/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/MSG' title='The Madison Square Garden Company'>MSG</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a> <font color='green'>+4%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+4%</font>. <a href='https://seekingalpha.com/symbol/EQGP' title='EQT GP Holdings LP'>EQGP</a> <font color='green'>+3%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports Inc.'>PIR</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/MOMT-OLD' title='MoneyOnMobile, Inc'>OTCQB:MOMT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/ZG' title='Zillow Group, Inc.'>ZG</a> <font color='red'>-3%</font>. <a href='https://seekingalpha.com/symbol/AXIM' title='Axim Biotechnologies, Inc.'>OTCQB:AXIM</a> <font color='red'>3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366717\" data-linked=\"After Hours Gainers / Losers (06/27/2018)\" data-tweet=\"$PED $PED $MSG - After Hours Gainers / Losers (06/27/2018) https://seekingalpha.com/news/3366717-after-hours-gainers-losers-06-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366717-after-hours-gainers-losers-06-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366715\" data-ts=\"1530134843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATH\" target=\"_blank\">ATH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366715-ft-athene-interested-in-ge-long-term-care-insurance-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FT: Athene interested in GE long-term care insurance assets</a></h4><ul>     <li>Athene Holding (NYSE:<a href='https://seekingalpha.com/symbol/ATH' title='Athene Holding'>ATH</a>)&nbsp;<font color='green'>+2.2%</font> after-hours has <a href=\"https://www.ft.com/content/f0274c2e-7a3b-11e8-8e67-1e1a0846c475\" target=\"_blank\">expressed interest in acquiring all or parts</a> of General Electric's (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>) long-term care insurance business, <em>Financial Times</em> reports.</li>     <li>Talks with ATH - the life insurance affiliate of P-E firm Apollo Global Management (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>) - are at an early stage, and GE likely will seek talks with multiple potential buyers, according to the report.</li>     <li>In announcing plans for a partial breakup of GE, CEO&nbsp;John Flannery said yesterday the company is \"aggressively working on actions and alternatives to mitigate, reduce or eliminate our exposure to long-term care insurance.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3366715\" data-linked=\"FT: Athene interested in GE long-term care insurance assets\" data-tweet=\"$ATH $ATH $GE - FT: Athene interested in GE long-term care insurance assets https://seekingalpha.com/news/3366715-ft-athene-interested-in-ge-long-term-care-insurance-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3366715-ft-athene-interested-in-ge-long-term-care-insurance-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366708\" data-ts=\"1530133951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDGE\" target=\"_blank\">EDGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366708-edge-therapeuticsplus-45_6-discloses-study-data-strategic-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edge Therapeutics +45.6% as it discloses study data, strategic update</a></h4><ul>   <li>Edge Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/EDGE' title='Edge Therapeutics'>EDGE</a>) is <font color='green'>up 45.6%</font> after hours after <a href=\"https://seekingalpha.com/pr/17203918-edge-therapeutics-announces-updated-results-phase-3-newton-2-study-egminus-1962-aneurysmal\" target=\"_blank\">posting an update</a> on its Phase 3 NEWTON 2 study that also contained strategic news.</li>    <li>The company says it continues to perform a review of strategic alternatives, having retained Piper Jaffray as an adviser, and those alternatives include \"an acquisition, merger, business combination or other strategic transaction involving Edge.\"</li>    <li>It says it's largely completed a worker streamlining, reducing headcount from 37 employees to 13.</li>    <li>Edge had discontinued the NEWTON 2 study (of EG-1962 in adults with aneurysmal subarachnoid hemorrhage) on the recommendation of a Data Monitoring Committee. The study was designed to detect a 15% absolute improvement in favorable outcomes with a target enrollment of 374 subjects.</li>    <li>Before discontinuation, 266 subjects completed a Day 90 follow-up, and 45% of subjects treated with a single intraventricular injection of EG-1962 showed a favorable outcome compared to 41% of subjects treated with oral nimodipine.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366708\" data-linked=\"Edge Therapeutics +45.6% as it discloses study data, strategic update\" data-tweet=\"$EDGE $PDSB - Edge Therapeutics +45.6% as it discloses study data, strategic update https://seekingalpha.com/news/3366708-edge-therapeuticsplus-45_6-discloses-study-data-strategic-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3366708-edge-therapeuticsplus-45_6-discloses-study-data-strategic-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366694\" data-ts=\"1530132247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/Z\" target=\"_blank\">Z</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366694-zillow-announces-class-c-senior-note-offerings-sharesminus-2_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zillow announces Class C, senior note offerings; shares -2.9%</a></h4><ul><li>        Zillow (NASDAQ:<a href='https://seekingalpha.com/symbol/Z' title='Zillow Group, Inc.'>Z</a>) <a href=\"https://seekingalpha.com/pr/17203897-zillow-group-announces-proposed-public-offerings-325-million-class-c-capital-stock-325\" target=\"_blank\">plans</a> concurrent public offerings of $325M in shares of its Class C stock and $325M of its convertible senior notes due 2023. The underwriters will have a 30-day option for up to $48.75M in addition shares and notes.</li><li>               Zillow shares are<font color='red'> down 2.9%</font>&nbsp;aftermarket to $58.96.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366694\" data-linked=\"Zillow announces Class C, senior note offerings; shares -2.9%\" data-tweet=\"$Z - Zillow announces Class C, senior note offerings; shares -2.9% https://seekingalpha.com/news/3366694-zillow-announces-class-c-senior-note-offerings-sharesminus-2_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3366694-zillow-announces-class-c-senior-note-offerings-sharesminus-2_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366692\" data-ts=\"1530131892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGS\" target=\"_blank\">PRGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366692-progress-softwareplus-4-on-q2-beats-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progress Software +4% on Q2 beats, in-line guidance</a></h4><ul><li>        Progress Software (NASDAQ:<a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a>)&nbsp;<font color='green'>gains 4%</font>&nbsp;aftermarket on Q2 results that beat EPS and revenue estimates with a 3% Y/Y revenue growth. In-line Q3 guidance has revenue form $95M to $97M (consensus: $97.93M) and EPs form $0.56 to $0.58 (consensus: $0.57).</li><li>               FY18 guidance has in-line revenue of $399M to $404M (consensus: $403.92) and upside EPS from $2.45 to $2.50 (consensus: $2.42).&nbsp;</li><li>               Earnings call is scheduled for 5 PM Eastern with a webcast available <a href=\"http://investors.progress.com/\" target=\"_blank\">here</a>.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17203878-progress-2018-second-quarter-results-exceed-guidance\" target=\"_blank\">Press release</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366682-progress-software-beats-0_07-beats-revenue\" target=\"_blank\">Progress Software beats by $0.07, beats on revenue</a> (June 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366685-progress-software-declares-0_14-dividend\" target=\"_blank\">Progress Software declares $0.14 dividend</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366692\" data-linked=\"Progress Software +4% on Q2 beats, in-line guidance\" data-tweet=\"$PRGS - Progress Software +4% on Q2 beats, in-line guidance https://seekingalpha.com/news/3366692-progress-softwareplus-4-on-q2-beats-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3366692-progress-softwareplus-4-on-q2-beats-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366691\" data-ts=\"1530131776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBBY\" target=\"_blank\">BBBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366691-bed-bath-beyondminus-5-store-sales-slipped-in-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bed Bath &amp; Beyond -5% as same-store sales slipped in Q1</a></h4><ul>     <li>Bed Bath &amp;&nbsp;Beyond (NASDAQ:<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>) <font color='red'>-5.6%</font> after-hours as it reports better than expected <a href=\"https://seekingalpha.com/news/3366680-bed-bath-and-beyond-beats-0_06-revenue-line\" target=\"_blank\">Q1 earnings</a> but a drop in comparable store sales.</li>     <li>While overall net sales edged 0.4% higher Y/Y, Q1 comp-store sales fell ~0.6% vs. expectations for a 0.2% gain: the company says Q1 results include strong sales growth from its customer-facing digital channels as well as from stores that declined in the mid-single-digit percentage range.</li>     <li>BBBY reaffirms guidance for FY 2019, seeing EPS in the low-to-mid $2.00 range vs. $2.27 analyst consensus estimate.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366691\" data-linked=\"Bed Bath &amp; Beyond -5% as same-store sales slipped in Q1\" data-tweet=\"$BBBY - Bed Bath &amp; Beyond -5% as same-store sales slipped in Q1 https://seekingalpha.com/news/3366691-bed-bath-beyondminus-5-store-sales-slipped-in-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3366691-bed-bath-beyondminus-5-store-sales-slipped-in-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366687\" data-ts=\"1530131229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAZZ\" target=\"_blank\">JAZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366687-fda-accepts-jazz-pharmas-xyrem-snda-pdufa-date-oct-27\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Jazz Pharma&#39;s Xyrem sNDA, PDUFA date Oct. 27</a></h4><ul><li>        Jazz Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/JAZZ' title='Jazz Pharmaceuticals, Inc.'>JAZZ</a>) <a href=\"https://seekingalpha.com/pr/17203869-jazz-pharmaceuticals-announces-fda-acceptance-supplemental-new-drug-application-xyrem-sodium\" target=\"_blank\">announces</a> that the FDA accepted for priority review its sNDA for Xyrem to include an indication for treating cataplexy and excessive daytime sleepiness in pediatric narcolepsy.</li><li>               The PDUFA date is October 27.&nbsp;</li><li>               Jazz shares are<font color='green'> up 0.3%</font>&nbsp;aftermarket to $175.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366687\" data-linked=\"FDA accepts Jazz Pharma&#39;s Xyrem sNDA, PDUFA date Oct. 27\" data-tweet=\"$JAZZ - FDA accepts Jazz Pharma&#39;s Xyrem sNDA, PDUFA date Oct. 27 https://seekingalpha.com/news/3366687-fda-accepts-jazz-pharmas-xyrem-snda-pdufa-date-oct-27?source=tweet\" data-url=\"https://seekingalpha.com/news/3366687-fda-accepts-jazz-pharmas-xyrem-snda-pdufa-date-oct-27\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366672\" data-ts=\"1530130111\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZFGN\" target=\"_blank\">ZFGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366672-zafen-raising-capital-shares-down-4_1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zafen raising capital; shares down 4.1%</a></h4><ul><li>The size of the stock offering isn't mentioned. Underwriters (Cowen and Piper) will get a greenshoe option for up to 15% of shares offered.</li><li><a href='https://seekingalpha.com/symbol/ZFGN' title='Zafgen, Inc.'>ZFGN</a><font color='red'> -4.1%</font>&nbsp;after hours</li><li>Source: <a href=\"https://seekingalpha.com/pr/17203830-zafgen-announces-proposed-offering-common-stock\" target=\"_blank\">Press Release</a></li><li><strong>Update</strong>: On July 2, the company <a href=\"https://seekingalpha.com/pr/17207330-zafgen-announces-closing-offering-common-stock-exercise-full-underwriters-option-purchase\" target=\"_blank\">announced </a>that it sold 9.2M shares of common stock at $7.50, including the full exercise of underwriters' option to buy 1.2M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366672\" data-linked=\"Zafen raising capital; shares down 4.1%\" data-tweet=\"$ZFGN - Zafen raising capital; shares down 4.1% https://seekingalpha.com/news/3366672-zafen-raising-capital-shares-down-4_1?source=tweet\" data-url=\"https://seekingalpha.com/news/3366672-zafen-raising-capital-shares-down-4_1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366666\" data-ts=\"1530129920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHF\" target=\"_blank\">BHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366666-brighthouse-drops-to-new-low-hobbled-bear-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brighthouse drops to new low, hobbled by bear market</a></h4><ul><li>Brighthouse Financial (<a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a> <font color='red'>-5.3%</font>)<font color='red'> fell 5.3%&nbsp;</font>to close at $40.23, earlier it touched $40.22, its lowest since it was spun off from MetLife (NYSE:<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a>) last August, and about a little more than a week after its former parent completely shed its stake.</li><li>Tim Travis, of T&amp;T Capital Management and an SA contributor, says the stock is highly correlated to equity markets, since the \"bear market could cause them to increase reserves on the variable annuity business.\"</li><li>On June 19, MetLife gave its remaining 23.2M BHF shares to Goldman Sachs (NYSE:<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a>), JPMorgan (NYSE:<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>), Morgan Stanley (NYSE:<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a>), and Wells Fargo (NYSE:<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a>) in exchange for MetLife debt held by the banks.</li><li>The banks sold the BHF shares in a secondary offering that was priced at $44.50 a share; BHF closed at $45.61 on that day.</li><li>A few days before the secondary offering, Credit Suisse analyst Andrew Kligerman predicted BHF would fall 5%-8% after the news that MetLife would exit its stake. As a result he cut his price target to $40.50 from $44. Since his note, BHF has fallen 12%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3365027-brighthouse-reports-closing-secondary-stock-offering\" target=\"_blank\">Brighthouse reports closing of secondary stock offering</a> (June 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366666\" data-linked=\"Brighthouse drops to new low, hobbled by bear market\" data-tweet=\"$BHF $BHF $MET - Brighthouse drops to new low, hobbled by bear market https://seekingalpha.com/news/3366666-brighthouse-drops-to-new-low-hobbled-bear-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3366666-brighthouse-drops-to-new-low-hobbled-bear-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366663\" data-ts=\"1530129307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQXP\" target=\"_blank\">AQXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366663-cantor-fitzgerald-slashes-aquinox-target-after-trial-failure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cantor Fitzgerald slashes its Aquinox target after trial failure</a></h4><ul><li>           Cantor Fitzgerald <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Cantor+Fitzgerald+Downgrades+Aquinox+Pharmaceutical+%28AQXP%29+to+Neutral/14348820.html\" target=\"_blank\">downgrades</a> Aquinox Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a>) form Buy to Neutral after this morning&rsquo;s trial failure announcement. </li><li> Firm slashes the price target from $28 to $2. </li><li> Aquinox shares are&nbsp;<font color='red'>down 85%</font>&nbsp;to $2.29. &nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3366459-aquinox-pharma-plunges-74-percent-trial-failure\" target=\"_blank\">Aquinox Pharma plunges 74% after trial failure</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366663\" data-linked=\"Cantor Fitzgerald slashes its Aquinox target after trial failure\" data-tweet=\"$AQXP $NLTX - Cantor Fitzgerald slashes its Aquinox target after trial failure https://seekingalpha.com/news/3366663-cantor-fitzgerald-slashes-aquinox-target-after-trial-failure?source=tweet\" data-url=\"https://seekingalpha.com/news/3366663-cantor-fitzgerald-slashes-aquinox-target-after-trial-failure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366662\" data-ts=\"1530129224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TM\" target=\"_blank\">TM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366662-toyota-warns-on-potential-tariff-says-camry-cost-rise-1800\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toyota warns on potential tariff, says Camry cost would rise $1,800</a></h4><ul>     <li>Toyota (<a href='https://seekingalpha.com/symbol/TM' title='Toyota Motor Corporation'>TM</a> <font color='red'>-1.5%</font>) warns a 25% tariff on auto imports would <a href=\"https://www.cnbc.com/2018/06/27/toyota-warns-trump-25-percent-auto-tariff-would-increase-cost-of-ever.html\" target=\"_blank\">increase the cost of every vehicle sold in the U.S.</a>, adding to the auto industry&rsquo;s criticism of the potential imposition of tariffs by Trump administration.</li>     <li>137K Americans \"support their families  working for Toyota, and Toyota and Lexus dealerships,\" the company says. \"They are not a national security threat. Indeed,  Toyota operates 10 manufacturing plants in the U.S. We are an exemplar  of the manufacturing might of America.\"</li>     <li>Specifically, TM says its Toyota Camry - made in Georgetown, Ky. - would face $1,800 per vehicle in increased costs.</li>     <li><a href=\"https://seekingalpha.com/news/3366414-auto-tariff-mean-45b-higher-costs-u-s-consumers-group-says\" target=\"_blank\">Yesterday</a>, the Alliance of Automobile Manufacturers said a 25% tariff would cost U.S. consumers $45B annually, or $5,800 per vehicle.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/RACE' title='Ferrari N.V.'>RACE</a>, <a href='https://seekingalpha.com/symbol/CARZ' title='First Trust NASDAQ Global Auto Index ETF'>CARZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3366662\" data-linked=\"Toyota warns on potential tariff, says Camry cost would rise $1,800\" data-tweet=\"$TM $TM $RACE - Toyota warns on potential tariff, says Camry cost would rise $1,800 https://seekingalpha.com/news/3366662-toyota-warns-on-potential-tariff-says-camry-cost-rise-1800?source=tweet\" data-url=\"https://seekingalpha.com/news/3366662-toyota-warns-on-potential-tariff-says-camry-cost-rise-1800\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366657\" data-ts=\"1530127823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAL\" target=\"_blank\">DAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366657-delta-air-lines-ceo-says-higher-jet-fuel-to-add-2b-to-costs-this-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delta Air Lines CEO says higher jet fuel to add $2B to costs this year</a></h4><ul>     <li>Delta Air Lines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='red'>-1.8%</font>) tumbles after CEO&nbsp;Ed Bastian says the company expects <a href=\"https://www.reuters.com/article/us-delta-air-outlook/delta-air-ceo-says-expects-2-billion-in-added-costs-on-higher-jet-fuel-expenses-idUSKBN1JN2P6?il=0\" target=\"_blank\">$2B in additional costs this year</a> due to the rising expense of jet fuel.</li>     <li>Earlier this month, DAL blamed a 50% annual increase in fuel costs for its decision to lower its Q2 EPS forecast to $1.65-$1.75 from its previous outlook of as much as $2.00/share, and rising jet fuel costs caused American Airlines to cut its full-year profit guidance in April.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366657\" data-linked=\"Delta Air Lines CEO says higher jet fuel to add $2B to costs this year\" data-tweet=\"$DAL - Delta Air Lines CEO says higher jet fuel to add $2B to costs this year https://seekingalpha.com/news/3366657-delta-air-lines-ceo-says-higher-jet-fuel-to-add-2b-to-costs-this-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3366657-delta-air-lines-ceo-says-higher-jet-fuel-to-add-2b-to-costs-this-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366654\" data-ts=\"1530127027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIZZ\" target=\"_blank\">FIZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366654-national-beverage-sinks-16-in-two-days-sec-asks-questions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">National Beverage sinks 16% in two days as SEC asks questions</a></h4><ul>     <li>LaCroix seltzer water maker National Beverage (<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-10.6%</font>) plunges 16% in two days after the <a href=\"https://www.cnbc.com/2018/06/27/shares-of-lacroix-maker-plunge-16percent-in-two-days-amid-sec-questions-abou.html\" target=\"_blank\">SEC raised questions</a> about some of the company&rsquo;s sales measurements.</li>     <li>The SEC asked FIZZ to explain the company's internal performance measures for sales - &ldquo;velocity per outlet&rdquo; and &ldquo;velocity per capita&rdquo; - which were referenced by CEO Nick Caporella in back-to back press releases last  year.</li><li>The comments piqued the interest of the SEC, which asked FIZZ to put the numbers into context, but the company declined the SEC's request, saying the information &ldquo;is as  secretive as the formulas of our beverages and should not be disclosed  to our competition.&rdquo;</li><li>&ldquo;The metrics [the CEO] referenced are used to establish goals  for certain customers, but are not utilized to manage the overall  executional side of our business,&rdquo; FIZZ chief accounting officer Gregory Cook told the SEC. &ldquo;VPO and VPC therefore  are not key performance indicators that would give readers a view of the  Company through the &lsquo;eyes of management.&rsquo;&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366654\" data-linked=\"National Beverage sinks 16% in two days as SEC asks questions\" data-tweet=\"$FIZZ - National Beverage sinks 16% in two days as SEC asks questions https://seekingalpha.com/news/3366654-national-beverage-sinks-16-in-two-days-sec-asks-questions?source=tweet\" data-url=\"https://seekingalpha.com/news/3366654-national-beverage-sinks-16-in-two-days-sec-asks-questions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366648\" data-ts=\"1530126019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGAN\" target=\"_blank\">EGAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366648-technology-top-5-gainers-losers-of-3-00-pm-06-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 PM (06/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/XPLR' title='Xplore Technologies Corp.'>XPLR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/RMNI' title='Rimini Street'>RMNI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-30%</font>. <a href='https://seekingalpha.com/symbol/LINK' title='Interlink Electronics'>LINK</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TSRI' title='TSR, Inc.'>TSRI</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366648\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 PM (06/27/2018)\" data-tweet=\"$EGAN $EGAN $NIHD - Technology - Top 5 Gainers / Losers as of 3:00 PM (06/27/2018) https://seekingalpha.com/news/3366648-technology-top-5-gainers-losers-of-3-00-pm-06-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366648-technology-top-5-gainers-losers-of-3-00-pm-06-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366641\" data-ts=\"1530123675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMMT\" target=\"_blank\">SMMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366641-summit-therapeuticsminus-80-after-discontinuing-top-drug-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Therapeutics -80% after discontinuing top drug candidate</a></h4><ul>     <li>Summit Therapeutics (<a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a> <font color='red'>-80.2%</font>) plunges ~80% to a 52-week low after its PhaseOut DMD <a href=\"https://seekingalpha.com/news/3366462-summit-therapeutics-announces-trial-failure-shares-halted\" target=\"_blank\">failed to meet</a> its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy, prompting the company to discontinue development of the drug.</li>     <li>\"Since our valuation was based mainly on the ezutromid program for DMD, we are <a href=\"https://www.streetinsider.com/Analyst+Comments/SunTrust+Robinson+Humphrey+Downgrades+Summit+Therapeutics+plc+%28SMMT%29+to+Hold/14349185.html\" target=\"_blank\">downgrading shares</a> to Hold from Buy and reducing our price target to $4 from $22,\" SunTrust says.</li>     <li>Ridinilazole, now SMMT's lead product candidate, is not expected to enter Phase 3 trials until Q1 2019, the firm notes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366641\" data-linked=\"Summit Therapeutics -80% after discontinuing top drug candidate\" data-tweet=\"$SMMT - Summit Therapeutics -80% after discontinuing top drug candidate https://seekingalpha.com/news/3366641-summit-therapeuticsminus-80-after-discontinuing-top-drug-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3366641-summit-therapeuticsminus-80-after-discontinuing-top-drug-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366640\" data-ts=\"1530122618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOMO\" target=\"_blank\">MOMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366640-momominus-6_9-on-spruce-point-report-alleging-serious-risks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momo -6.9% on Spruce Point report alleging &quot;serious risks&quot;</a></h4><ul><li>           Spruce Point is <a href=\"https://www.sprucepointcap.com/momo-inc/\" target=\"_blank\">out with a report</a> on Momo (NASDAQ:<a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a>) and sees $23 to $32/share or 30% to 50% downside risk after &ldquo;primary forensic research&rdquo; with Spruce&rsquo;s China-based investigator. </li><li> Key quote from Spruce: &ldquo;Momo&rsquo;s investor base is compromised of two distinct cohorts, fundamental investors taking management&rsquo;s word at face value and momentum/swing traders trying to play the stock&rsquo;s trend. Both of these groups are oblivious to the serious risks underpinning a Momo investment.&rdquo; </li><li> Momo shares are&nbsp;<font color='red'>down 6.9%</font>&nbsp;to $42.20. &nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3366640\" data-linked=\"Momo -6.9% on Spruce Point report alleging &quot;serious risks&quot;\" data-tweet=\"$MOMO - Momo -6.9% on Spruce Point report alleging &quot;serious risks&quot; https://seekingalpha.com/news/3366640-momominus-6_9-on-spruce-point-report-alleging-serious-risks?source=tweet\" data-url=\"https://seekingalpha.com/news/3366640-momominus-6_9-on-spruce-point-report-alleging-serious-risks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366637\" data-ts=\"1530122457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MXC\" target=\"_blank\">MXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366637-energy-materials-top-5-gainers-losers-of-2-00-pm-06-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ESV' title='Ensco PLC'>ESV</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/DO' title='Diamond Offshore Drilling Inc.'>DO</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/HLX' title='Helix Energy Solutions Group, Inc.'>HLX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/RDC' title='Rowan Companies plc'>RDC</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CNXM' title='CNX Midstream Partners LP'>CNXM</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services'>TUSK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CEIX' title='CONSOL Energy Inc.'>CEIX</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366637\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/27/2018)\" data-tweet=\"$MXC $MXC $VAL - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/27/2018) https://seekingalpha.com/news/3366637-energy-materials-top-5-gainers-losers-of-2-00-pm-06-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366637-energy-materials-top-5-gainers-losers-of-2-00-pm-06-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366636\" data-ts=\"1530122377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366636-summit-insights-gives-twitter-street-high-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Insights gives Twitter Street-high price target</a></h4><ul>   <li>Summit Insights is in with Wall Street's highest price target on Twitter (<a href=\"http://seekingalpha.com/symbol/TWTR\" target=\"_blank\">TWTR</a> <font color='red'>-1.9%</font>): $52, up from a previous $35.</li>    <li>That implies 18.2% upside from current pricing.</li>    <li>The platform has opportunities in live sports partnerships and can seize a mantle as the \"source of breaking news\" particularly with Facebook's (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) withdrawal there amid data-scandal issues, analyst Jonathan Kees writes. Ad dollars will grow as brands spend more, and international will be a big growth driver. (h/t Bloomberg)</li>    <li>Twitter shares are <font color='green'>up 86.8%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366636\" data-linked=\"Summit Insights gives Twitter Street-high price target\" data-tweet=\"$FB $FB $TWTR - Summit Insights gives Twitter Street-high price target https://seekingalpha.com/news/3366636-summit-insights-gives-twitter-street-high-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3366636-summit-insights-gives-twitter-street-high-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366633\" data-ts=\"1530121931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WAGE\" target=\"_blank\">WAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366633-wageworksminus-5_6-after-stifel-target-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WageWorks -5.6% after Stifel target cut</a></h4><ul><li>        Stifel <a href=\"https://www.streetinsider.com/Analyst+PT+Change/WageWorks+%28WAGE%29+PT+Lowered+to+%2464+at+Stifel/14346874.html\" target=\"_blank\">maintains</a> a Buy rating on WageWorks (NYSE:<a href='https://seekingalpha.com/symbol/WAGE' title='WageWorks, Inc.'>WAGE</a>) and lowers its price target from $80 to $64, a 25% upside to yesterday&rsquo;s close.</li><li>               WageWorks shares are&nbsp;<font color='red'>down 5.6%</font>&nbsp;to $48.35. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366633\" data-linked=\"WageWorks -5.6% after Stifel target cut\" data-tweet=\"$WAGE - WageWorks -5.6% after Stifel target cut https://seekingalpha.com/news/3366633-wageworksminus-5_6-after-stifel-target-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3366633-wageworksminus-5_6-after-stifel-target-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366631\" data-ts=\"1530121305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QQQ\" target=\"_blank\">QQQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366631-tech-leads-averages-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech leads averages lower</a></h4><ul><li>Markets opened higher after the president relented on Chinese tech investments, but the Nasdaq (<a href='https://seekingalpha.com/symbol/QQQ' title='Invesco QQQ ETF'>QQQ</a> <font color='red'>-0.4%</font>) is leading the way lower in afternoon action. The S&amp;P 500 is down just 0.2%.</li><li>Among tech names with sizable losses are Oracle&nbsp;<font color='red'>down 1.5%</font>, Texas Instrument&nbsp;<font color='red'>down 1.6%</font>, and Intel&nbsp;<font color='red'>down 1.3%</font>.</li><li>Stumbling markets are helping Treasurys catch a bid, with the 10-year yield down five basis points to 2.83%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366489-trump-takes-softer-expected-approach-foreign-tech-investments\" target=\"_blank\">Trump takes softer than expected approach to foreign tech investments</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366631\" data-linked=\"Tech leads averages lower\" data-tweet=\"$QQQ - Tech leads averages lower https://seekingalpha.com/news/3366631-tech-leads-averages-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3366631-tech-leads-averages-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366630\" data-ts=\"1530121131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366630-array-biopharma-gets-fda-approval-for-melanoma-combo-treatment-shares-halted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array BioPharma gets FDA approval for melanoma combo treatment; shares halted</a></h4><ul><li>        The FDA <a href=\"https://www.reuters.com/article/uk-array-biopharma-fda/arrays-melanoma-combo-treatment-wins-fda-approval-idUSKBN1JN2JX\" target=\"_blank\">approves</a> Array BioPharma&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) combo treatment of encorafenib and binimetinib for patients with advanced melanoma associated with a BRAF mutation.</li><li>                  Array shares were halted at 12:52 PM pending the news.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3366630\" data-linked=\"Array BioPharma gets FDA approval for melanoma combo treatment; shares halted\" data-tweet=\"$ARRY - Array BioPharma gets FDA approval for melanoma combo treatment; shares halted https://seekingalpha.com/news/3366630-array-biopharma-gets-fda-approval-for-melanoma-combo-treatment-shares-halted?source=tweet\" data-url=\"https://seekingalpha.com/news/3366630-array-biopharma-gets-fda-approval-for-melanoma-combo-treatment-shares-halted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366626\" data-ts=\"1530120358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZEN\" target=\"_blank\">ZEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366626-zendesk-gets-target-boost-appoints-first-chief-people-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zendesk gets target boost, appoints first Chief People Officer</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Zendesk+%28ZEN%29+PT+Raised+to+%2465+at+Morgan+Stanley/14347089.html\" target=\"_blank\">maintains</a> an Overweight rating on Zendesk (NYSE:<a href='https://seekingalpha.com/symbol/ZEN' title='Zendesk, Inc.'>ZEN</a>) but raises the price target from $62 to $65.</li><li>               In other Zendesk news, the company <a href=\"https://seekingalpha.com/pr/17203646-zendesk-names-inamarie-johnson-chief-people-officer\" target=\"_blank\">appoints</a> InaMarie Johnson as its first Chief People Officer, a role overseeing human resources, talent acquisition, and workplace experience functions.</li><li>               Johnson was most recently SVP and Chief Human Resources Officer at Plantronics and previously worked in the same role at UTI Worldwide. &nbsp;&nbsp;</li><li>               Zendesk shares are<font color='red'> down 1.5%</font>&nbsp;to $53.66.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366626\" data-linked=\"Zendesk gets target boost, appoints first Chief People Officer\" data-tweet=\"$ZEN - Zendesk gets target boost, appoints first Chief People Officer https://seekingalpha.com/news/3366626-zendesk-gets-target-boost-appoints-first-chief-people-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3366626-zendesk-gets-target-boost-appoints-first-chief-people-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366625\" data-ts=\"1530120029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366625-justice-dept-signs-off-on-disneys-71b-fox-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Justice Dept. signs off on Disney&#39;s $71B Fox deal</a></h4><ul>   <li>The Justice Dept. <a href=\"https://www.justice.gov/opa/pr/walt-disney-company-required-divest-twenty-two-regional-sports-networks-order-complete\" target=\"_blank\">made its sign-off official</a> on Disney's $71.3B acquisition of media assets from Twenty-First Century Fox.</li>    <li>That comes via a civil antitrust suit filed by the DOJ's antitrust division today, along with a simultaneous settlement that resolves alleged competitive harm by requiring the divestment of 22 Fox regional sports networks.</li>    <li>That's a move Disney's already agreed to do, rather than go forward with more delays and face the suit. The settlement deal requires court approval.</li><li>Under a consent decree, Disney would have 90 days after closing the deal to complete selling off the RSNs, with a possible 90-day extension.</li>    <li>&ldquo;American consumers have benefited from head-to-head competition between Disney and Fox&rsquo;s cable sports programming that ultimately has prevented cable television subscription prices from rising even higher,&rdquo; said DOJ antitrust chief Makan Delrahim. &ldquo;Today&rsquo;s settlement will ensure that sports programming competition is preserved in the local markets where Disney and Fox compete for cable and satellite distribution.&rdquo;</li><li>What's next? The deal needs foreign approvals as well as the OK from shareholders of both companies. No meeting is set as yet.</li>    <li>Currently: <a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a> <font color='green'>+0.8%</font>; <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+1.2%</font>; <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+1.6%</font>; <a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='red'>-0.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366625\" data-linked=\"Justice Dept. signs off on Disney&#39;s $71B Fox deal\" data-tweet=\"$DIS $DIS $FOX - Justice Dept. signs off on Disney&#39;s $71B Fox deal https://seekingalpha.com/news/3366625-justice-dept-signs-off-on-disneys-71b-fox-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3366625-justice-dept-signs-off-on-disneys-71b-fox-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366621\" data-ts=\"1530119103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDC\" target=\"_blank\">CLDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366621-midday-gainers-losers-06-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (06/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='green'>+56%</font>. <a href='https://seekingalpha.com/symbol/MXC' title='Mexco Energy Corporation'>MXC</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/AINC' title='Ashford Inc.'>AINC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corp.'>ATLC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a> <font color='red'>-84%</font>. <a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a> <font color='red'>-80%</font>. <a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a> <font color='red'>-70%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='red'>-39%</font>. <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-29%</font>. <a href='https://seekingalpha.com/symbol/ASCMA' title='Ascent Capital Group, Inc.'>ASCMA</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/YECO-OLD' title='Yulong Eco-Materials'>YECO-OLD</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/CADC' title='China Advanced Construction Materials Group, Inc.'>CADC</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/KZIA' title='Kazia Therapeutics Ltd'>KZIA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a> <font color='red'>-16%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366621\" data-linked=\"Midday Gainers / Losers (06/27/2018)\" data-tweet=\"$CLDC $CLDC $MXC - Midday Gainers / Losers (06/27/2018) https://seekingalpha.com/news/3366621-midday-gainers-losers-06-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366621-midday-gainers-losers-06-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366619\" data-ts=\"1530118867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDC\" target=\"_blank\">CLDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366619-financials-top-5-gainers-losers-of-1-00-pm-06-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (06/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='green'>+58%</font>. <a href='https://seekingalpha.com/symbol/AINC' title='Ashford Inc.'>AINC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corp.'>ATLC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TREE' title='LendingTree, Inc.'>TREE</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/GEC' title='Great Elm Capital Group, Inc.'>GEC</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366619\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (06/27/2018)\" data-tweet=\"$CLDC $CLDC $AINC - Financials - Top 5 Gainers / Losers as of 1:00 PM (06/27/2018) https://seekingalpha.com/news/3366619-financials-top-5-gainers-losers-of-1-00-pm-06-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366619-financials-top-5-gainers-losers-of-1-00-pm-06-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366610\" data-ts=\"1530116717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OZM\" target=\"_blank\">OZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366610-oz-management-gains-after-ge-capital-aviation-portfolio-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oz Management gains after GE Capital Aviation portfolio deal</a></h4><ul><li>Oz Management (NYSE:<a href='https://seekingalpha.com/symbol/OZM' title='Och-Ziff Capital Management Group LLC'>OZM</a>)&nbsp;<font color='green'>+3.7%&nbsp;</font>after announcing that it will serve as asset manager for a GE (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>) Capital Aviation Services portfolio deal.</li><li>The gain comes after OZM hit a 52-week low of $1.91 yesterday; its 52-week high of $3.95 occurred on Oct. 30.</li><li>The agreement starts with the formation of STARR 2018-1, called START Ltd., an entity that will buy a portfolio of aircraft from GECAS. START Ltd. will finance the acquisition with 144A debt and equity.</li><li>GECAS will service the portfolio and Oz will serve as asset manager.</li><li>The goal is that Oz will improve liquidity for debt and equity investors by providing providing enhanced investor reporting.</li><li>Oz will also be&nbsp;an asset manager for potential future transactions, acting on behalf of the syndicated equity investors as an adviser to the board regarding portfolio matters.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17202880-gecas-b-oz-b-b-management-b-close-starr-2018minus-1\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3346378-oz-management-appoints-thomas-m-sipp-cfo\" target=\"_blank\">OZ Management appoints Thomas M. Sipp CFO</a> (April 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366610\" data-linked=\"Oz Management gains after GE Capital Aviation portfolio deal\" data-tweet=\"$OZM $SCU $GE - Oz Management gains after GE Capital Aviation portfolio deal https://seekingalpha.com/news/3366610-oz-management-gains-after-ge-capital-aviation-portfolio-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3366610-oz-management-gains-after-ge-capital-aviation-portfolio-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366606\" data-ts=\"1530116483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AU\" target=\"_blank\">AU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366606-ghana-issues-environmental-permits-to-reopen-anglogolds-obuasi-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ghana issues environmental permits to reopen AngloGold&#39;s Obuasi mine</a></h4><ul>     <li>AngloGold Ashanti (<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='red'>-2.6%</font>) says it <a href=\"http://www.mining.com/ghana-oks-anglogold-plan-reopen-mine-battled-illegal-miners/\" target=\"_blank\">received environmental permits</a> from Ghana's government to reopen its Obuasi mine, paving the way for redevelopment of the mine after halting operations at the end of 2014 after suffering from substantial financial losses.</li><li>&ldquo;With the key permitting and regulatory process complete, we will  continue to progress the redevelopment of the Obuasi mine as a modern,  productive, operation that will benefit a range of key stakeholders for  at least two decades,&rdquo; the company says.</li><li>AU expects to start gold production at Obuasi by Q3 2019 at an  initial cost of $450M-$500M over the  first two and a half years, with annual gold production seen averaging 350K-450K oz. during the first 10 years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366606\" data-linked=\"Ghana issues environmental permits to reopen AngloGold&#39;s Obuasi mine\" data-tweet=\"$AU - Ghana issues environmental permits to reopen AngloGold&#39;s Obuasi mine https://seekingalpha.com/news/3366606-ghana-issues-environmental-permits-to-reopen-anglogolds-obuasi-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/3366606-ghana-issues-environmental-permits-to-reopen-anglogolds-obuasi-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366598\" data-ts=\"1530115253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FORK\" target=\"_blank\">FORK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366598-consumer-top-gainers-losers-of-12-00-pm-06-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 PM (06/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FORK' title='Fuling Global'>FORK</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/THST' title='Truett-Hurst, Inc.'>THST</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/JRSH' title='Jerash Holdings &#40;US&#41; Inc'>JRSH</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/EAST' title='Eastside Distilling, Inc.'>EAST</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/VIRC' title='Virco Manufacturing Corporation'>VIRC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366598\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 PM (06/27/2018)\" data-tweet=\"$FORK $FORK $THST - Consumer - Top Gainers / Losers as of 12:00 PM (06/27/2018) https://seekingalpha.com/news/3366598-consumer-top-gainers-losers-of-12-00-pm-06-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366598-consumer-top-gainers-losers-of-12-00-pm-06-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366595\" data-ts=\"1530114622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCG\" target=\"_blank\">SCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366595-scanaminus-3-south-carolina-lawmakers-reach-deal-to-cut-rates-nearly-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCANA -3% as South Carolina lawmakers reach deal to cut rates nearly 15%</a></h4><ul>     <li>SCANA (<a href='https://seekingalpha.com/symbol/SCG' title='SCANA Corporation'>SCG</a> <font color='red'>-3.7%</font>) sinks after South Carolina lawmakers reach a deal to temporarily <a href=\"https://www.thestate.com/news/politics-government/article213886594.html\" target=\"_blank\">lower electric rates by nearly 15%</a> at its SCE&amp;G unit, virtually wiping out the portion of the utility's power bills that customers now pay for the abandoned construction of two unfinished nuclear reactors.</li>     <li>The rate cut also could cause Dominion Energy, which has offered to buy out SCG, to withdraw that offer and its proposed benefits, including $1,000 checks to SCE&amp;G customers and a $10/month rate cut, <em>The State</em> reports.</li>     <li>SCE&amp;G is expected to challenge the rate cut in court if it is passed and signed into law by the governor, who has said he would veto any proposal that allows SCE&amp;G to continue charging its customers anything for the failed nuclear project.</li>     <li><a href=\"https://seekingalpha.com/news/3348920-south-carolina-house-votes-13-percent-sce-and-g-rate-cut-small\" target=\"_blank\">Earlier</a>: South Carolina House votes down 13% SCE&amp;G rate cut as too small (Apr. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366595\" data-linked=\"SCANA -3% as South Carolina lawmakers reach deal to cut rates nearly 15%\" data-tweet=\"$SCG - SCANA -3% as South Carolina lawmakers reach deal to cut rates nearly 15% https://seekingalpha.com/news/3366595-scanaminus-3-south-carolina-lawmakers-reach-deal-to-cut-rates-nearly-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3366595-scanaminus-3-south-carolina-lawmakers-reach-deal-to-cut-rates-nearly-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366589\" data-ts=\"1530114283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366589-dj-doj-to-approve-disneys-71b-fox-deal-soon-today-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DJ: DOJ to approve Disney&#39;s $71B Fox deal as soon as today (updated)</a></h4><ul>   <li>The Justice Dept. is expected to approve Walt Disney's (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) $71.3B purchase of Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a>) media assets <a href=\"https://www.wsj.com/articles/justice-department-expected-to-ok-disneys-proposed-purchase-of-fox-assets-1530114027?mod=searchresults&amp;page=1&amp;pos=1\" target=\"_blank\">as soon as today</a>, Dow Jones is reporting.</li>    <li>On the move: <a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a> <font color='green'>+1.4%</font>; <a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='red'>-0.3%</font>; <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+1.4%</font>; <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+1.8%</font>.</li><li><strong>Updated 11:55 a.m.:</strong> As part of this approval, Disney's agreeing to divest Fox's regional sports networks.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366521-wsj-comcast-bring-partners-fox-firepower\" target=\"_blank\">WSJ: Comcast could bring partners for more Fox firepower</a> (Jun. 27 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366353-murdoch-losing-cash-components-fox-bids-grow\" target=\"_blank\">Murdoch losing as cash components of Fox bids grow</a> (Jun. 26 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366303-fox-filing-antitrust-issues-scuttle-comcast-bid\" target=\"_blank\">Fox filing: Antitrust issues could scuttle Comcast bid</a> (Jun. 26 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366589\" data-linked=\"DJ: DOJ to approve Disney&#39;s $71B Fox deal as soon as today (updated)\" data-tweet=\"$DIS $DIS $FOX - DJ: DOJ to approve Disney&#39;s $71B Fox deal as soon as today (updated) https://seekingalpha.com/news/3366589-dj-doj-to-approve-disneys-71b-fox-deal-soon-today-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3366589-dj-doj-to-approve-disneys-71b-fox-deal-soon-today-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366587\" data-ts=\"1530113696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366587-ge-climbs-another-4-after-oppenheimer-upgrade-on-break-up-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE climbs another 4% after Oppenheimer upgrade on break-up plans</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='green'>+3.7%</font>) shoots higher, extending yesterday's 7.7% surge, after Oppenheimer <a href=\"https://www.cnbc.com/2018/06/27/general-electric-upgraded-as-wall-street-lauds-spin-off-plans.html\" target=\"_blank\">upgrades</a> shares to Perform from Underperform, citing the \"potential for [GE's] portfolio plan to unlock some value, and diminish liabilities.\"</li>     <li>\"GE can reduce net leverage by $25 billion by 2020, from Healthcare liability transfer (debt and pension) allocation of $18 billion gross and meaningful planned liquidity from break-up moves,\" analyst Christopher Glynn writes.</li>     <li>Glynn is <a href=\"https://www.barrons.com/articles/ge-getting-its-groove-back-1530111252?mod=hp_RTA\" target=\"_blank\">upbeat on GE's break-up plans</a> for its divisions, and estimates the health care unit may fetch $50B in equity value, while the Baker Hughes stake is worth $23.5B and the pending transaction for its transportation unit, expected early next year, could yield a value of more than $12B.</li><li><a href=\"https://seekingalpha.com/news/3366477-jpmorgan-maintains-negative-view-ge\" target=\"_blank\">Earlier</a>: J.P. Morgan maintains negative view on GE&nbsp;(June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366587\" data-linked=\"GE climbs another 4% after Oppenheimer upgrade on break-up plans\" data-tweet=\"$GE - GE climbs another 4% after Oppenheimer upgrade on break-up plans https://seekingalpha.com/news/3366587-ge-climbs-another-4-after-oppenheimer-upgrade-on-break-up-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3366587-ge-climbs-another-4-after-oppenheimer-upgrade-on-break-up-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366578\" data-ts=\"1530112691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCSG\" target=\"_blank\">HCSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366578-healthcare-services-groupplus-5_8-on-jefferies-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Services Group +5.8% on Jefferies upgrade</a></h4><ul><li>        Jefferies <a href=\"https://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+Healthcare+Services+Group+%28HCSG%29+to+Buy/14346561.html\" target=\"_blank\">upgrades</a> Healthcare Services Group (NASDAQ:<a href='https://seekingalpha.com/symbol/HCSG' title='Healthcare Services Group, Inc.'>HCSG</a>) from Hold to Buy and increases the price target from $40 to $53, a 27% upside to yesterday&rsquo;s close. &nbsp;</li><li>        Healthcare Services shares are&nbsp;<font color='green'>up 5.8%&nbsp;</font>to $44.05.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366578\" data-linked=\"Healthcare Services Group +5.8% on Jefferies upgrade\" data-tweet=\"$HCSG - Healthcare Services Group +5.8% on Jefferies upgrade https://seekingalpha.com/news/3366578-healthcare-services-groupplus-5_8-on-jefferies-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3366578-healthcare-services-groupplus-5_8-on-jefferies-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366573\" data-ts=\"1530111633\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGS\" target=\"_blank\">MDGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366573-healthcare-top-5-gainers-losers-of-11-00-06-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/27/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/CKPT' title='CHECKPOINT THERAPEUTICS'>CKPT</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/APTX' title='Aptinyx'>APTX</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a> <font color='red'>-84%</font>. <a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a> <font color='red'>-80%</font>. <a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a> <font color='red'>-70%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='red'>-46%</font>. <a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a> <font color='red'>-18%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366573\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/27/2018)\" data-tweet=\"$MDGS $MDGS $CARA - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (06/27/2018) https://seekingalpha.com/news/3366573-healthcare-top-5-gainers-losers-of-11-00-06-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366573-healthcare-top-5-gainers-losers-of-11-00-06-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366570\" data-ts=\"1530111012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366570-intelsatplus-10-kerrisdale-endorses-spectrum-proposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat +10% as Kerrisdale endorses spectrum proposal</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>) has <font color='green'>jumped 9.9%</font> today as short-seller Kerrisdale Capital Management says it's <a href=\"https://seekingalpha.com/article/4184057-intelsat-s-ses-s-moon\" target=\"_blank\">long on the satellite company's idea</a> to monetize C-band spectrum.</li>    <li>Intelsat and SES (<a href=\"http://seekingalpha.com/symbol/SGBAF\" target=\"_blank\">SGBAF</a> <font color='red'>-0.8%</font>), in partnership with Intel (<a href=\"http://seekingalpha.com/symbol/INTC\" target=\"_blank\">INTC</a> <font color='green'>+0.6%</font>), have proposed sharing satellite spectrum in 3.7 GHz-4.2 GHz with wireless providers as a way of unlocking value.</li>    <li>\"We are long shares of Intelsat and SES,\" Kerrisdale says, \"an unusual position to be in\" given its past attacks on spectrum hype.</li>    <li>\"But this time, it&rsquo;s different. Intelsat and SES hold the keys to the right frequencies, in the right way, at the right time, without the irreconcilable interference issues that have beset other spectrum stories,\" the firm says.</li>    <li>The proposal is the best and fastest way to value in this \"crucial\" spectrum, it says.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3365303-intelsat-now-27-percent-fcc-set-vote-c-band-usage\" target=\"_blank\">Intelsat now up 27% with FCC set to vote on C-band usage</a> (Jun. 20 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3365199-intelsat-plus-9-percent-rbc-raises-outperform-c-band-prospects\" target=\"_blank\">Intelsat +9% as RBC raises to Outperform on C-band prospects</a> (Jun. 20 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366570\" data-linked=\"Intelsat +10% as Kerrisdale endorses spectrum proposal\" data-tweet=\"$I $I $SGBAF - Intelsat +10% as Kerrisdale endorses spectrum proposal https://seekingalpha.com/news/3366570-intelsatplus-10-kerrisdale-endorses-spectrum-proposal?source=tweet\" data-url=\"https://seekingalpha.com/news/3366570-intelsatplus-10-kerrisdale-endorses-spectrum-proposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366569\" data-ts=\"1530111006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APC\" target=\"_blank\">APC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366569-anadarko-sees-decision-on-mozambique-lng-export-terminal-h1-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anadarko sees decision on Mozambique LNG export terminal by H1 2019</a></h4><ul>     <li>Anadarko Petroleum (<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='green'>+3%</font>) says it expects to finalize sales and financing agreements ahead of a <a href=\"https://www.reuters.com/article/gas-conference-anadarko-petrol/anadarko-expects-to-decide-on-investment-in-mozambique-lng-export-terminal-in-2019-idUSL1N1TT0OA\" target=\"_blank\">final investment decision in H1 2019</a> to build the first liquefied natural gas export terminal in Mozambique.</li>     <li>APC&rsquo;s executive VP for international, deepwater and exploration Mitch Ingram tells the World Gas Conference in Washington, D.C., that the company is <a href=\"https://www.ft.com/content/d34685b2-7995-11e8-bc55-50daf11b720d\" target=\"_blank\">ready to move forward</a> with the Mozambique project after lining up enough deals with customers, approvals from the government and preparing for construction work.</li><li>The project is in a &ldquo;sweet spot,\" Ingram says, because the worldwide slowdown in approvals means there has been less competition both for customers and for suppliers to build the facilities, and it is hitting the contractors &ldquo;at the low end of the cost cycle.\"</li><li>APC and its partners Mitsui of Japan and ONGC&nbsp;Videsh of India expect to spend ~$7.7B for the gas liquefaction and export plant plus an unspecified amount for offshore wells and pipelines, after significant cost reductions over the past couple of years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366569\" data-linked=\"Anadarko sees decision on Mozambique LNG export terminal by H1 2019\" data-tweet=\"$APC - Anadarko sees decision on Mozambique LNG export terminal by H1 2019 https://seekingalpha.com/news/3366569-anadarko-sees-decision-on-mozambique-lng-export-terminal-h1-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3366569-anadarko-sees-decision-on-mozambique-lng-export-terminal-h1-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366566\" data-ts=\"1530110897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELTK\" target=\"_blank\">ELTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366566-eltek-down-12-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eltek down 12% post Q1 results</a></h4><ul><li>Eltek (<a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='red'>-12.1%</font>) reported Q1 revenue growth of 4.7% Y/Y to $8.9M, while still facing issues with its manufacturing operations.</li><li>Q1 Overall margins: Gross&nbsp;<font color='red'>declined by 76 bps</font>&nbsp;to 4.9%, operating&nbsp;<font color='green'>recovered by 44 bps</font>&nbsp;to -7% and Adj. EBITDA<font color='green'> recovered by 41 bps</font>&nbsp;to -2.07%.</li><li>Q1 Expenses: SG&amp;A $1.07M (-2.4% Y/Y) and R&amp;D declined by 94.7% Y/Y to 1k.</li><li>Net cash used in operating activities $856k (+15.34% Y/Y).</li><li>Company had cash and equivalents of $435k as of March 31, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366455-eltek-reports-q1-results\" target=\"_blank\">Eltek reports Q1 results</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366566\" data-linked=\"Eltek down 12% post Q1 results\" data-tweet=\"$ELTK - Eltek down 12% post Q1 results https://seekingalpha.com/news/3366566-eltek-down-12-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3366566-eltek-down-12-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366564\" data-ts=\"1530110514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366564-raymond-james-buy-nvidia-ahead-of-gaming-chip-launch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James: Buy Nvidia ahead of gaming chip launch</a></h4><ul><li>           Raymond James <a href=\"https://www.cnbc.com/2018/06/27/buy-nvidia-because-its-new-gaming-chips-will-launch-soon-analyst.html\" target=\"_blank\">reiterates</a> Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) at Outperform and $300 price target (24% upside) and says to buy shares ahead of the new gaming chips launching soon. </li><li> Analyst Chris Caso cites mid-quarter channel partner checks and says the firm feels &ldquo;very comfortable with our 2H18 estimates for both Gaming and Datacenter following those checks.&rdquo; </li><li> Caso has &ldquo;increased conviction that the October quarter will benefit from a new gaming product cycle, which we expect to be a catalyst and potential source of upside.&rdquo; </li><li> The analyst expects Nvidia&rsquo;s gaming segment sales to increase 10% Q/Q in the October quarter. </li><li> Nvidia shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $244.44. &nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3366564\" data-linked=\"Raymond James: Buy Nvidia ahead of gaming chip launch\" data-tweet=\"$NVDA - Raymond James: Buy Nvidia ahead of gaming chip launch https://seekingalpha.com/news/3366564-raymond-james-buy-nvidia-ahead-of-gaming-chip-launch?source=tweet\" data-url=\"https://seekingalpha.com/news/3366564-raymond-james-buy-nvidia-ahead-of-gaming-chip-launch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366561\" data-ts=\"1530110281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366561-crude-futures-up-on-sharp-inventory-decline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures up on sharp inventory decline</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-9.9</strong><strong>M</strong> barrels vs. -2.6M consensus, -5.9M last week.</li><li>Gasoline <strong>+1.2</strong><strong>M</strong> barrels vs. +1.3M consensus, +3.3M last week.</li><li>Distillates <strong>+0.01</strong><strong>M</strong> barrels vs. +0.8M consensus, +2.8M last week.</li><li>Futures&nbsp;<font color='green'>+2.5%</font>&nbsp;to $72.30.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3366561\" data-linked=\"Crude futures up on sharp inventory decline\" data-tweet=\"$USO $OIL $UCO - Crude futures up on sharp inventory decline https://seekingalpha.com/news/3366561-crude-futures-up-on-sharp-inventory-decline?source=tweet\" data-url=\"https://seekingalpha.com/news/3366561-crude-futures-up-on-sharp-inventory-decline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>102&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366554\" data-ts=\"1530108927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366554-global-blood-therapeutics-target-hiked-to-street-high-96-cantor-fitzgerald\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Blood Therapeutics target hiked to Street-high $96 at Cantor Fitzgerald</a></h4><ul>     <li>Global Blood Therapeutics (<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='red'>-4.4%</font>) is lower as investors apparently overlook <a href=\"https://seekingalpha.com/news/3366490-global-blood-minus-7-percent-despite-positive-data-sickle-cell-drug-trial\" target=\"_blank\">positive results</a> for a late-stage trial of its sickle cell disease therapy and instead focus on the company's decision not to enroll any more patients for testing until it finishes discussions with the FDA.</li>     <li>CEO Ted Love said earlier this year that GBT <a href=\"https://www.marketwatch.com/story/global-blood-therapeutics-reports-positive-data-in-trial-of-sickle-cell-disease-treatment-2018-06-27-7914036\" target=\"_blank\">planned to enroll ~400 patients</a> in the trial, compared with the 154 patients enrolled in part A, according to MarketWatch.</li>     <li>But Cantor Fitzgerald analysts are impressed enough with the results to <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Global+Blood+Therapeutics+%28GBT%29+PT+Raised+to+Street+High+%2496+at+Cantor+Fitzgerald/14348044.html\" target=\"_blank\">raise their GBT price target to $96</a> from $69, saying the trial provides further support of the voxelotor treatment's potential for approval; the firm raises its probability of success for the drug to 75% from 70%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366554\" data-linked=\"Global Blood Therapeutics target hiked to Street-high $96 at Cantor Fitzgerald\" data-tweet=\"$GBT - Global Blood Therapeutics target hiked to Street-high $96 at Cantor Fitzgerald https://seekingalpha.com/news/3366554-global-blood-therapeutics-target-hiked-to-street-high-96-cantor-fitzgerald?source=tweet\" data-url=\"https://seekingalpha.com/news/3366554-global-blood-therapeutics-target-hiked-to-street-high-96-cantor-fitzgerald\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366552\" data-ts=\"1530108833\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366552-report-snap-preparing-gaming-platform-for-fall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Snap preparing gaming platform for fall</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) has <font color='green'>popped 2.1%</font> after a report in The Information says it's <a href=\"https://www.theinformation.com/articles/snap-gaming-platform-coming-this-fall\" target=\"_blank\">readying a platform for game developers</a>.</li>    <li>That's set to launch this fall and would allow for games to be played through the Snapchat app, according to the report.</li>    <li>The company has at least one publisher lined up to make a game for the platform.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366552\" data-linked=\"Report: Snap preparing gaming platform for fall\" data-tweet=\"$SNAP - Report: Snap preparing gaming platform for fall https://seekingalpha.com/news/3366552-report-snap-preparing-gaming-platform-for-fall?source=tweet\" data-url=\"https://seekingalpha.com/news/3366552-report-snap-preparing-gaming-platform-for-fall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366551\" data-ts=\"1530108761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEES\" target=\"_blank\">HEES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366551-ubs-gives-h-and-e-equipment-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS gives H&amp;E Equipment a boost</a></h4><ul><li>H&amp;E Equipment (NASDAQ:<a href='https://seekingalpha.com/symbol/HEES' title='H&E Equipment Services, Inc.'>HEES</a>) is eager to meet a fresh <a href=\"https://utahherald.com/hu0026e-equipment-services-hees-was-upgraded-by-ubs-to-neutral-federated-premier-municipal-income-fund-has-1-4-sentiment/\" target=\"_blank\">forecast</a> from UBS, <font color='green'>soaring 7.4%</font> in early trade to meet the firm's new price target of $39.</li><li>Analyst Steven Fisher upgraded HEES to Neutral from Sell, citing higher oil prices that will allow companies to spend more on projects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366551\" data-linked=\"UBS gives H&amp;E Equipment a boost\" data-tweet=\"$HEES - UBS gives H&amp;E Equipment a boost https://seekingalpha.com/news/3366551-ubs-gives-h-and-e-equipment-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3366551-ubs-gives-h-and-e-equipment-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366539\" data-ts=\"1530107666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAC\" target=\"_blank\">DAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366539-danaos-jumps-11-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Danaos jumps 11% post Q1 results</a></h4><ul><li>Danaos (<a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='green'>+11.1%</font>) reported Q1 revenue of $111.85M (+1.6% Y/Y) the increase was due to the re-chartering of certain vessels at higher rates.</li><li>Q1 overall operating margin<font color='green'> improved by 448 bps&nbsp;</font>to 42.7% and Adj. EBITDA margin<font color='green'> improved by 262 bps&nbsp;</font>to 68.5%.</li><li>Q1 expenses: Vessel operating $26.8M (-2.5% Y/Y), G&amp;A $5.2M (-14.7% Y/%) and Voyage $3.2M (-15.8% Y/Y).</li><li>Company&rsquo;s fleet utilization for the quarter was 95.6%, with an average of 55 containerships and an average gross daily charter rate of $23,628.</li><li>Total contracted revenues were $1.7B as of March 31, 2018, with chatters extending to 2028 and average duration of 5.4 years.</li><li>&ldquo;In the near term, we maintain high charter contract coverage of 90% for the next 12 months based on current operating revenues and 81% in terms of contracted operating days. The charter market has stabilized at current levels although trade tensions tend to make liner companies hesitant to commit for longer periods. The benefit, conversely, may be a reduction of speculative ordering or ordering by liner companies, a condition that would improve market conditions&rdquo;, commented Dr. John Coustas, CEO.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366375-danaos-beats-0_07-beats-revenue\" target=\"_blank\">Danaos beats by $0.07, beats on revenue</a> (June 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366539\" data-linked=\"Danaos jumps 11% post Q1 results\" data-tweet=\"$DAC - Danaos jumps 11% post Q1 results https://seekingalpha.com/news/3366539-danaos-jumps-11-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3366539-danaos-jumps-11-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366538\" data-ts=\"1530107133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/W\" target=\"_blank\">W</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366538-piper-jaffray-raises-wayfair-to-new-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray raises Wayfair to new Street-high target</a></h4><ul><li>        Piper Jaffray raises its Wayfair (NYSE:<a href='https://seekingalpha.com/symbol/W' title='Wayfair'>W</a>) price target to a Street-high $150 from $96.</li><li>        Target represents a 34% upside to yesterday&rsquo;s close.&nbsp;</li><li>               Source: Bloomberg First Word.&nbsp;</li><li>               Wayfair shares are&nbsp;<font color='green'>up 1.8%</font>&nbsp;to $114.17. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366538\" data-linked=\"Piper Jaffray raises Wayfair to new Street-high target\" data-tweet=\"$W - Piper Jaffray raises Wayfair to new Street-high target https://seekingalpha.com/news/3366538-piper-jaffray-raises-wayfair-to-new-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3366538-piper-jaffray-raises-wayfair-to-new-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366535\" data-ts=\"1530106770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SELB\" target=\"_blank\">SELB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366535-selecta-biosciencesplus-5_6-on-janney-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selecta Biosciences +5.6% on Janney initiation</a></h4><ul><li>           Janney Montgomery Scott <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Janney+Starts+Selecta+Biosciences+%28SELB%29+at+Buy/14346700.html\" target=\"_blank\">initiates</a> Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences'>SELB</a>) with a Buy rating and a $33 price target. </li><li> Selecta shares are<font color='green'> up $5.6%</font>&nbsp;to $13.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3366535\" data-linked=\"Selecta Biosciences +5.6% on Janney initiation\" data-tweet=\"$SELB - Selecta Biosciences +5.6% on Janney initiation https://seekingalpha.com/news/3366535-selecta-biosciencesplus-5_6-on-janney-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3366535-selecta-biosciencesplus-5_6-on-janney-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366532\" data-ts=\"1530106382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTE\" target=\"_blank\">PTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366532-polarityte-responds-to-citron-research-fraud-claims\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PolarityTE responds to Citron Research fraud claims</a></h4><ul><li>        PolarityTE (COOL) <a href=\"https://seekingalpha.com/pr/17203009-polarityte-provides-update-key-opinion-leader-event-addresses-misleading-report\" target=\"_blank\">responds</a> to the Citron Research report earlier this week accusing the company of fraud in raising money on a rejected patent application, saying the SEC should launch an investigation.</li><li>               PolarityTE says the statements about a &ldquo;non-final rejection&rdquo; and a &ldquo;final rejection&rdquo; notice from the USPTO refer to office actions, which are a &ldquo;normal patent prosecution process&rdquo; with opportunities for the company to respond to the USPTO and the ability to continue prosecution.&nbsp;</li><li>               The company &ldquo;strongly disputes&rdquo; claims that any current directors or officers have sold shares in the past 12 months and says the claim mischaracterizes registration of the securities issuable under an incentive plan, a routine event that doesn&rsquo;t equal a share sale.&nbsp;</li><li>               PolarityTE shares were up premarket but&nbsp;<font color='red'>dip 0.4%</font>&nbsp;at the open to $26.31.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366057-polarityte-minus-28-percent-citron-accuses-fraud\" target=\"_blank\">PolarityTE -28% after Citron accuses fraud</a> (June 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366532\" data-linked=\"PolarityTE responds to Citron Research fraud claims\" data-tweet=\"$PTE - PolarityTE responds to Citron Research fraud claims https://seekingalpha.com/news/3366532-polarityte-responds-to-citron-research-fraud-claims?source=tweet\" data-url=\"https://seekingalpha.com/news/3366532-polarityte-responds-to-citron-research-fraud-claims\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366529\" data-ts=\"1530106103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQXP\" target=\"_blank\">AQXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366529-premarket-losers-of-9-05-6-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (6/27/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a>&nbsp;<font color='red'>-83%</font>&nbsp;after trial <a href=\"https://seekingalpha.com/news/3366459-aquinox-pharma-plunges-74-percent-trial-failure\" target=\"_blank\">failure</a>.</li>     <li><a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a>&nbsp;<font color='red'>-79%</font>&nbsp;after trial&nbsp;<a href=\"https://seekingalpha.com/news/3366462-summit-therapeutics-announces-trial-failure-shares-halted\" target=\"_blank\">failure</a></li>     <li><a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a>&nbsp;<font color='red'>-76%&nbsp;</font>after <a href=\"https://seekingalpha.com/news/3366410-durect-minus-10_9-percent-ptie-minus-75-percent-failed-remoxy-vote\" target=\"_blank\">failed</a> Remoxy vote.</li>     <li><a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a>&nbsp;<font color='red'>-32%</font>&nbsp;as Cel-Sci <a href=\"https://seekingalpha.com/pr/17202912-cel-sci-wins-breach-contract-ruling-clinical-research-organization-inventiv-now-known-syneos\" target=\"_blank\">wins</a> breach of contract ruling against clinical research organization inVentiv.</li>     <li><a href='https://seekingalpha.com/symbol/DRRX' title='Durect Corporation'>DRRX</a>&nbsp;<font color='red'>-22%</font>&nbsp;after&nbsp;<a href=\"https://seekingalpha.com/news/3366410-durect-minus-10_9-percent-ptie-minus-75-percent-failed-remoxy-vote\" target=\"_blank\">failed</a>&nbsp;Remoxy vote.</li>     <li><a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a>&nbsp;<font color='red'>-20%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a>&nbsp;<font color='red'>-15%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a>&nbsp;<font color='red'>-12%</font>&nbsp;<a href=\"https://seekingalpha.com/news/3366490-global-blood-minus-7-percent-despite-positive-data-sickle-cell-drug-trial\" target=\"_blank\">despite</a> positive data from sickle cell drug trial.</li>     <li><a href='https://seekingalpha.com/symbol/CNXM' title='CNX Midstream Partners LP'>CNXM</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3366478-cnx-midstream-partners-lp-announces-pricing-upsized-secondary-public-offering\" target=\"_blank\">announcing</a> pricing of upsized secondary public offering.</li>     <li><a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a>&nbsp;<font color='red'>-9%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3366363-aerovironment-beats-0_31-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/ERII' title='Energy Recovery, Inc.'>ERII</a><font color='red'>-8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/SBLK' title='Star Bulk Carriers Corp.'>SBLK</a>&nbsp;<font color='red'>-8%</font>&nbsp;after largest shareholder <a href=\"https://seekingalpha.com/news/3366481-star-bulk-carriers-minus-7-percent-largest-shareholder-sells-5m-shares\" target=\"_blank\">sells</a> 5M shares.</li>     <li><a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>&nbsp;<font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366529\" data-linked=\"Premarket Losers as of 9:05 am (6/27/2018)\" data-tweet=\"$AQXP $NLTX $SMMT - Premarket Losers as of 9:05 am (6/27/2018) https://seekingalpha.com/news/3366529-premarket-losers-of-9-05-6-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366529-premarket-losers-of-9-05-6-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366528\" data-ts=\"1530106045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366528-netflixplus-2-bofa-boosts-target-on-global-opportunity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix +2% as BofA boosts target on global opportunity</a></h4><ul>    <li>Following on yesterday's <font color='green'>3.9% rebound</font>, Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <font color='green'>up 2%</font> premarket today with BofA Merrill Lynch raising its price target to $460, from $352.</li>    <li>There's still a lot of upside ahead if the streamer can hit even \"conservative\" penetration levels with its international push, analyst Nat Schindler says. The company's original content build-out will be an important asset and support its pricing power in the long term. (h/t Bloomberg)</li>    <li>Netflix gained yesterday after picking up a <a href=\"https://seekingalpha.com/news/3366185-netflix-gains-another-wall-street-bull-shares-1_7-percent-premarket\" target=\"_blank\">new bull</a> via an Outperform rating from Imperial Capital.</li><li>The new BofA target implies 15%&nbsp;upside; shares have already more than doubled year-to-date.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3366528\" data-linked=\"Netflix +2% as BofA boosts target on global opportunity\" data-tweet=\"$NFLX - Netflix +2% as BofA boosts target on global opportunity https://seekingalpha.com/news/3366528-netflixplus-2-bofa-boosts-target-on-global-opportunity?source=tweet\" data-url=\"https://seekingalpha.com/news/3366528-netflixplus-2-bofa-boosts-target-on-global-opportunity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366525\" data-ts=\"1530105612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCYX\" target=\"_blank\">SCYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366525-scynexisplus-7_1-on-maxim-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scynexis +7.1% on Maxim initiation</a></h4><ul><li>        Maxim <a href=\"https://www.streetinsider.com/Analyst+Comments/Maxim+Group+Starts+SCYNEXIS+%28SCYX%29+at+Buy/14347112.html\" target=\"_blank\">starts</a> Scynexis (NASDAQ:<a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a>) with a Buy rating citing valuation and the potential upside from antifungal SCY-078.</li><li>               Scynexis shares are&nbsp;<font color='green'>up 7.1%</font>&nbsp;premarket to $1.82.&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366525\" data-linked=\"Scynexis +7.1% on Maxim initiation\" data-tweet=\"$SCYX - Scynexis +7.1% on Maxim initiation https://seekingalpha.com/news/3366525-scynexisplus-7_1-on-maxim-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3366525-scynexisplus-7_1-on-maxim-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366521\" data-ts=\"1530105465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366521-wsj-comcast-bring-partners-for-fox-firepower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Comcast could bring partners for more Fox firepower</a></h4><ul>   <li>Comcast (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) -- now on the back foot in a bidding war against Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) for media assets of Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a>) -- may <a href=\"https://www.wsj.com/articles/comcast-hunts-for-additional-cash-in-pursuit-of-21st-century-fox-assets-1530103147?mod=e2tw\" target=\"_blank\">tap strategic partners or private equity</a> for more capital, <i>The Wall Street Journal</i> reports.</li>    <li>That's not the current plan, the report suggests, but it could come into play if bidding hits $90B or so. Disney's $71.3B deal is the one in play at the moment.</li>    <li>And it could mean splitting the assets, sending things like U.S. assets to the partner while Comcast holds international broadcast units like Sky (<a href='https://seekingalpha.com/symbol/SKYAY' title='Sky Plc ADR'>OTCPK:SKYAY</a>) and Star India.</li>    <li>Premarket: <a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a> <font color='red'>-0.4%</font>; <a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a> <font color='green'>+0.5%</font>; <a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+1.6%</font>; <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+1.7%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366353-murdoch-losing-cash-components-fox-bids-grow\" target=\"_blank\">Murdoch losing as cash components of Fox bids grow</a> (Jun. 26 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366303-fox-filing-antitrust-issues-scuttle-comcast-bid\" target=\"_blank\">Fox filing: Antitrust issues could scuttle Comcast bid</a> (Jun. 26 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3365713-disney-set-double-asset-sales-secure-fox-deal\" target=\"_blank\">Disney set to double asset sales to secure Fox deal</a> (Jun. 21 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366521\" data-linked=\"WSJ: Comcast could bring partners for more Fox firepower\" data-tweet=\"$CMCSA $CMCSA $DIS - WSJ: Comcast could bring partners for more Fox firepower https://seekingalpha.com/news/3366521-wsj-comcast-bring-partners-for-fox-firepower?source=tweet\" data-url=\"https://seekingalpha.com/news/3366521-wsj-comcast-bring-partners-for-fox-firepower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366520\" data-ts=\"1530105409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGS\" target=\"_blank\">MDGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366520-premarket-gainers-of-9-05-6-27-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (6/27/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='green'>+46%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17202474-medigus-enters-orthopedic-market-new-development-manufacturing-agreement-integrated\" target=\"_blank\">entering</a> into a development agreement with A.M. Surgical.</li>     <li><a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+32%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3366464-cara-therapeutics-reports-positive-top-line-v-cr845\" target=\"_blank\">positive</a> top-line on I.V. CR845.</li>     <li><a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+24%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3366433-arcadia-biosciences-announces-partnership-farmer-s-business-network-inc\" target=\"_blank\">partnership</a> with Farmer&rsquo;s Business Network.</li>     <li><a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3366396-wwe-plus-8_1-percent-new-u-s-flagship-deals-usa-fox\" target=\"_blank\">new</a> U.S. flagship deals with USA, Fox.</li>     <li><a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+9%</font>&nbsp;on pulmonary fibrosis patent.</li>     <li><a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+12%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17203167-gevo-adopts-dsm-s-eboost-yeast-ethanol\" target=\"_blank\">adopting</a> Royal DSM&rsquo;s new&nbsp;<em>e</em>BOOST yeast at its production facility in&nbsp;Luverne.</li>     <li><a href='https://seekingalpha.com/symbol/UAVS' title='AgEagle'>UAVS</a> <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CLPS' title='CLPS, Inc'>CLPS</a> <font color='green'>+5%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3366472-clps-reports-q3-results\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a> <font color='green'>+6%</font>&nbsp;on SCY-078 <a href=\"https://seekingalpha.com/pr/17202956-scynexis-announces-presentation-scyminus-078-data-teratology-society-58th-annual-meeting\" target=\"_blank\">data</a> at the teratology society 58th annual meeting.</li>     <li><a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='green'>+11%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3366375-danaos-beats-0_07-beats-revenue\" target=\"_blank\">result</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3366520\" data-linked=\"Premarket Gainers as of 9:05 am (6/27/2018)\" data-tweet=\"$MDGS $MDGS $CARA - Premarket Gainers as of 9:05 am (6/27/2018) https://seekingalpha.com/news/3366520-premarket-gainers-of-9-05-6-27-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3366520-premarket-gainers-of-9-05-6-27-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366518\" data-ts=\"1530105224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRX\" target=\"_blank\">ACRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366518-acelrxplus-3_9-on-ec-approval-for-dzuveo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AcelRx +3.9% on EC approval for Dzuveo</a></h4><ul><li>        AcelRx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a>) <a href=\"https://finviz.com/screener.ashx?v=111&amp;s=ta_toplosers&amp;f=sec_technology\" target=\"_blank\">announces</a> that the European Commission has approved Dzuveo (or Dsuvia in the US) for managing acute moderate to severe pain in adults in medically monitored settings.</li><li>               The approval marks AcelRx&rsquo;s second EC approval, following Zalviso.&nbsp;</li><li>               Dsuvia has a PDUFA date of November 3. &nbsp;&nbsp;</li><li>               AcelRx shares are&nbsp;<font color='green'>up 3.9%</font>&nbsp;premarket to $4.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366518\" data-linked=\"AcelRx +3.9% on EC approval for Dzuveo\" data-tweet=\"$ACRX - AcelRx +3.9% on EC approval for Dzuveo https://seekingalpha.com/news/3366518-acelrxplus-3_9-on-ec-approval-for-dzuveo?source=tweet\" data-url=\"https://seekingalpha.com/news/3366518-acelrxplus-3_9-on-ec-approval-for-dzuveo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366516\" data-ts=\"1530105013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANTH\" target=\"_blank\">ANTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366516-anthera-pharma-to-be-delisted-tomorrow-shares-down-33_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anthera Pharma to be delisted tomorrow; shares down 33.5%</a></h4><ul><li>The company has withdrawn its request for a hearing to appeal its delisting determination at Nasdaq. Trading will be suspended at the open tomorrow.</li><li><a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a><font color='red'> -33.5%</font>&nbsp;to $0.18.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17202964-b-anthera-b-pharmaceuticals-announces-withdrawal-nasdaq-hearing-request-suspension-trading\" target=\"_blank\">Press Release</a></li><li>Previously:&nbsp;<a href=\"https://seekingalpha.com/news/3338268-anthera-terminate-development-sollpura-failed-late-stage-study\" target=\"_blank\">Anthera to terminate development of Sollpura after failed late-stage study</a>&nbsp;(March 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366516\" data-linked=\"Anthera Pharma to be delisted tomorrow; shares down 33.5%\" data-tweet=\"$ANTH - Anthera Pharma to be delisted tomorrow; shares down 33.5% https://seekingalpha.com/news/3366516-anthera-pharma-to-be-delisted-tomorrow-shares-down-33_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3366516-anthera-pharma-to-be-delisted-tomorrow-shares-down-33_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366512\" data-ts=\"1530104710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366512-galectinplus-9_3-on-pulmonary-fibrosis-patent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galectin +9.3% on pulmonary fibrosis patent</a></h4><ul><li>        Galectin (NASDAQ:<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>) <a href=\"https://seekingalpha.com/pr/17202952-galectin-therapeutics-receives-patent-gr-mdminus-02-patent-method-treatment-pulmonary\" target=\"_blank\">receives</a> a patent for pulmonary fibrosis. The patent is expected to cover the use of GR-MD-02 for compositions, methods of use, and methods of manufacturing compositions. The patent coverage extends to 2032.</li><li>               Galectin Therapeutics shares are&nbsp;<font color='green'>up 9.3%</font>&nbsp;premarket to $6.83.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366512\" data-linked=\"Galectin +9.3% on pulmonary fibrosis patent\" data-tweet=\"$GALT - Galectin +9.3% on pulmonary fibrosis patent https://seekingalpha.com/news/3366512-galectinplus-9_3-on-pulmonary-fibrosis-patent?source=tweet\" data-url=\"https://seekingalpha.com/news/3366512-galectinplus-9_3-on-pulmonary-fibrosis-patent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366508\" data-ts=\"1530104073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOMO\" target=\"_blank\">MOMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366508-momo-prices-650m-senior-note-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Momo prices $650M senior note offering</a></h4><ul><li>        Momo (NASDAQ:<a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a>) <a href=\"https://seekingalpha.com/pr/17202955-momo-inc-prices-offering-us-650-million-convertible-senior-notes\" target=\"_blank\">prices</a> a $650M offering of convertible senior notes due 2025. Initial purchasers get a 30-day option for an additional $100M. The offering is expected to close on July 2.</li><li>               Momo shares are<font color='green'> up 0.9%</font>&nbsp;premarket to $45.76. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366508\" data-linked=\"Momo prices $650M senior note offering\" data-tweet=\"$MOMO - Momo prices $650M senior note offering https://seekingalpha.com/news/3366508-momo-prices-650m-senior-note-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3366508-momo-prices-650m-senior-note-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366504\" data-ts=\"1530103613\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPY\" target=\"_blank\">SPY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366504-futures-turn-positive-trump-backs-down-on-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Futures turn positive as Trump backs down on China</a></h4><ul><li>Instead of invoking a little-used national emergency law to block Chinese investments in U.S. technology companies, the White House will push Congress to strengthen CFIUS, <a href=\"https://www.bloomberg.com/news/articles/2018-06-27/trump-seeks-to-bolster-government-panel-to-curb-china-investment?utm_source=twitter&amp;utm_content=tictoc&amp;cmpid%3D=socialflow-twitter-tictoc&amp;utm_campaign=socialflow-organic&amp;utm_medium=social\" target=\"_blank\">according to</a> multiple reports.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366489-trump-takes-softer-expected-approach-foreign-tech-investments\" target=\"_blank\">Trump takes softer than expected approach to foreign tech investments</a> (June 27)</li><li>S&amp;P 500 (NYSEARCA:<a href='https://seekingalpha.com/symbol/SPY' title='SPDR S&P 500 Trust ETF'>SPY</a>) futures have<font color='green'> added 0.5%</font>&nbsp;since the news hit, now&nbsp;<font color='green'>up 0.15%</font>&nbsp;on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366504\" data-linked=\"Futures turn positive as Trump backs down on China\" data-tweet=\"$SPY - Futures turn positive as Trump backs down on China https://seekingalpha.com/news/3366504-futures-turn-positive-trump-backs-down-on-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3366504-futures-turn-positive-trump-backs-down-on-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366503\" data-ts=\"1530103600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366503-baiduplus-2_2-on-1b-share-repurchase-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baidu +2.2% on $1B share repurchase program</a></h4><ul><li>        Baidu&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) board <a href=\"https://seekingalpha.com/pr/17202738-baidu-announces-us-1-billion-share-repurchase-program\" target=\"_blank\">approves</a> a $1B share repurchase program of over the next 12 months.</li><li>                  Baidu shares are&nbsp;<font color='green'>up 2.2%</font>&nbsp;premarket to $256.19.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3366503\" data-linked=\"Baidu +2.2% on $1B share repurchase program\" data-tweet=\"$BIDU - Baidu +2.2% on $1B share repurchase program https://seekingalpha.com/news/3366503-baiduplus-2_2-on-1b-share-repurchase-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3366503-baiduplus-2_2-on-1b-share-repurchase-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366489\" data-ts=\"1530101348\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366489-trump-takes-softer-expected-approach-to-foreign-tech-investments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump takes softer than expected approach to foreign tech investments</a></h4><ul><li>        The White House <a href=\"https://www.cnbc.com/2018/06/27/treasury-secretary-mnuchin.html\" target=\"_blank\">won&rsquo;t block</a> companies with 25% or more of Chinese ownership from buying certain US tech-related companies, marking a less strict approach than anticipated.</li><li>               The government will rely on the newly strengthened Committee on Foreign Investment in the US (CFIUS) to handle concerns about foreign purchases of sensitive domestic tech, according to a CNBC source.&nbsp;</li><li>               Stock futures broke turned positive on the news after previously indicating a lower open.&nbsp;</li><li>               Tech stocks that could move on the news include Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) and NXP Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>) since the acquisition deal depends on China&rsquo;s approval and semiconductor stocks.&nbsp;&nbsp;</li><li>Semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a>.</li><li>        Qualcomm shares are&nbsp;<font color='red'>down 1.6%</font>&nbsp;premarket. NXP shares are&nbsp;<font color='green'>up 1.2%</font>.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366489\" data-linked=\"Trump takes softer than expected approach to foreign tech investments\" data-tweet=\"$QCOM $QCOM $NXPI - Trump takes softer than expected approach to foreign tech investments https://seekingalpha.com/news/3366489-trump-takes-softer-expected-approach-to-foreign-tech-investments?source=tweet\" data-url=\"https://seekingalpha.com/news/3366489-trump-takes-softer-expected-approach-to-foreign-tech-investments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366484\" data-ts=\"1530100843\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSII\" target=\"_blank\">CSII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366484-cardiovascular-systems-gets-two-notch-upgrade-baml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardiovascular Systems gets two-notch upgrade at BAML</a></h4><ul><li>One catalyst not being paid enough attention to is the company's July 31 investor day, says analyst Bob Hopkins. New projects and opportunities coming in the relatively near-term will be highlighted, he says, and investors should leave the meeting more convinced that double-digit revenue growth is sustainable.</li><li>He upgrades Cardiovascular Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CSII' title='Cardiovascular Systems, Inc.'>CSII</a>) to Buy from Underperform and lifts his price target to $40 from $30. That would be about 33% upside from yesterday's close.</li><li>Alongside, Hopkins downgrades NuVasive (NASDAQ:<a href='https://seekingalpha.com/symbol/NUVA' title='NuVasive, Inc.'>NUVA</a>) and Globus Medical (NYSE:<a href='https://seekingalpha.com/symbol/GMED' title='Globus Medical'>GMED</a>) to Underperform.</li><li>Source: Bloomberg</li><li>CSII&nbsp;<font color='green'>+1.1%</font>, NUVA&nbsp;<font color='red'>-1.7%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3366484\" data-linked=\"Cardiovascular Systems gets two-notch upgrade at BAML\" data-tweet=\"$CSII $CSII $NUVA - Cardiovascular Systems gets two-notch upgrade at BAML https://seekingalpha.com/news/3366484-cardiovascular-systems-gets-two-notch-upgrade-baml?source=tweet\" data-url=\"https://seekingalpha.com/news/3366484-cardiovascular-systems-gets-two-notch-upgrade-baml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366482\" data-ts=\"1530100629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366482-rosenblatt-initiates-twilio-22-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt initiates Twilio at 22% upside</a></h4><ul><li>           Rosenblatt <a href=\"https://www.streetinsider.com/Hot+New+Coverage/Rosenblatt+Starts+Twilio+%28TWLO%29+at+Buy/14347136.html\" target=\"_blank\">initiates</a> Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) with a Buy rating and a $70 price target, a 22% upside to yesterday&rsquo;s close. </li><li>           Twilio shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket to $58. &nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3366482\" data-linked=\"Rosenblatt initiates Twilio at 22% upside\" data-tweet=\"$TWLO - Rosenblatt initiates Twilio at 22% upside https://seekingalpha.com/news/3366482-rosenblatt-initiates-twilio-22-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3366482-rosenblatt-initiates-twilio-22-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366481\" data-ts=\"1530100457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBLK\" target=\"_blank\">SBLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366481-star-bulk-carriersminus-7-after-largest-shareholder-sells-5m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Star Bulk Carriers -7% after largest shareholder sells 5M shares</a></h4><ul>     <li>Star Bulk Carriers (NASDAQ:<a href='https://seekingalpha.com/symbol/SBLK' title='Star Bulk Carriers Corp.'>SBLK</a>) <font color='red'>-7.6%</font> premarket after <a href=\"https://seekingalpha.com/pr/17202884-star-bulk-carriers-corp-announces-pricing-secondary-public-offering-5000-000-common-shares\" target=\"_blank\">pricing a 5M-share secondary offering</a> by top shareholder Oaktree Capital Management at $13.10/share, or 6.9% below Tuesday's closing price of $14.07.</li><li>Oaktree had owned 32.58M SBLK shares as of March 31, 50.8% of shares outstanding; after the offering, SBLK says Oaktree will own ~43% of shares outstanding.</li><li><a href=\"https://seekingalpha.com/news/3366403-star-bulk-carriers-announces-secondary-public-offering\" target=\"_blank\">Earlier</a>: Star Bulk Carriers announces secondary public offering (June 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366481\" data-linked=\"Star Bulk Carriers -7% after largest shareholder sells 5M shares\" data-tweet=\"$SBLK - Star Bulk Carriers -7% after largest shareholder sells 5M shares https://seekingalpha.com/news/3366481-star-bulk-carriersminus-7-after-largest-shareholder-sells-5m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3366481-star-bulk-carriersminus-7-after-largest-shareholder-sells-5m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366480\" data-ts=\"1530100347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366480-marvell-technologyplus-1_3-analysts-get-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell Technology +1.3% as analysts get bullish</a></h4><ul><li>        Evercore initiates Marvell Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a>) at Outperform with a $27 price target, a 36% upside to yesterday&rsquo;s close.</li><li>               Analyst C.J. Muse says the &ldquo;third wave&rdquo; of compute led by AI, big data, and storage is perceived as having more value. Muse sees demand for higher semi content led by data centers and cloud, benefitting Marvell.&nbsp;</li><li>               Muse notes that Marvell&rsquo;s underperformance this year makes for a compelling entry point.&nbsp;</li><li>               More action: Deutsche Bank upgrades Marvell to Buy from Hold with a $24 price target due to the recent pullback.&nbsp;</li><li>               Analyst Ross Seymore sees the Cavium deal as a positive short-term catalyst that will drive long-term strength.&nbsp;</li><li>               Seymore says Marvell is one of the few semi names with potential upsides in valuation and earnings.&nbsp;</li><li>               Source: Bloomberg First Word.&nbsp;</li><li>               Marvell Technology shares are&nbsp;<font color='green'>up 1.3%</font>&nbsp;premarket to $20.17.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366480\" data-linked=\"Marvell Technology +1.3% as analysts get bullish\" data-tweet=\"$MRVL - Marvell Technology +1.3% as analysts get bullish https://seekingalpha.com/news/3366480-marvell-technologyplus-1_3-analysts-get-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3366480-marvell-technologyplus-1_3-analysts-get-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366476\" data-ts=\"1530099670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366476-b-riley-starts-abeona-therapeutics-61-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">B. Riley starts Abeona Therapeutics at 61% upside</a></h4><ul><li>        B. Riley <a href=\"https://www.streetinsider.com/Hot+New+Coverage/B.RileyFBR+Starts+Abeona+Therapeutics+%28ABEO%29+at+Buy%2C+Positive+Early-Stage+Clinical+Trial+Results+Underpin+Cell+%26+Gene+Therapy+Platform+for+Rare+Diseases/14346530.html\" target=\"_blank\">initiates</a> Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) at Buy with a $26 price target, a 61% upside to yesterday&rsquo;s close.</li><li>                  Firm cites positive early-stage results that underpin the cell and gene therapy platform.    </li><li>               Abeona Therapeutics shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket to $16.30.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366476\" data-linked=\"B. Riley starts Abeona Therapeutics at 61% upside\" data-tweet=\"$ABEO - B. Riley starts Abeona Therapeutics at 61% upside https://seekingalpha.com/news/3366476-b-riley-starts-abeona-therapeutics-61-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3366476-b-riley-starts-abeona-therapeutics-61-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366471\" data-ts=\"1530099243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIS\" target=\"_blank\">GIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366471-on-general-mills-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on General Mills&#39; Q4 results</a></h4><ul><li>General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>) reports organic net sales rose 1% in&nbsp;<a href=\"https://seekingalpha.com/pr/17202843-general-mills-reports-fourth-quarter-full-year-fiscal-2018-results-provides-2019-outlook\" target=\"_blank\">Q4</a>, primarily reflecting benefits from organic net price realization and mix across all four operating segments.</li><li>North America Retail sales flat at $2.39B and operating profit +7% to $543M.</li><li>Convenience Stores and Foodservice sales +5% to $511M and operating profit increased 11% to $117M.</li><li>Europe &amp;&nbsp;Australia sales grew 14% to $556M and operating profit expanded 55% to $57M.</li><li>Asia and Latin America sales down 1% to $435M.</li><li>Adjusted gross margin rate improved 70 bps to 35.8%.</li><li>SG&amp;A expense rate flat at 18.2%.</li><li>Adjusted operating margin rate up 170 bps to 18.5%.</li><li><b>FY2019 Guidance</b>: Organic net sales: flat to +1%%&nbsp;; Adjusted operating margin: +6% to +9% (on a constant currency basis);&nbsp;Adjusted EPS:&nbsp;flat to -3% (on a constant currency basis).</li><li>GIS&nbsp;<font color='green'>+0.43%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366452-general-mills-beats-0_07-revenue-line\" target=\"_blank\">General Mills beats by $0.07,  revenue in-line</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366471\" data-linked=\"More on General Mills&#39; Q4 results\" data-tweet=\"$GIS - More on General Mills&#39; Q4 results https://seekingalpha.com/news/3366471-on-general-mills-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3366471-on-general-mills-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366470\" data-ts=\"1530099118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OKTA\" target=\"_blank\">OKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366470-oktaplus-1_5-needham-steps-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Okta +1.5% as Needham steps to Buy</a></h4><ul><li>        Needham <a href=\"https://www.streetinsider.com/Analyst+Comments/Needham+%26+Company+Upgrades+Okta%2C+Inc+%28OKTA%29+to+Buy/14346803.html\" target=\"_blank\">upgrades</a> Okta (NASDAQ:<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a>) from Hold to Buy with a $58 price target, a 17% upside to yesterday&rsquo;s close.</li><li>               Okta shares are&nbsp;<font color='green'>up 1.5%</font>&nbsp;premarket to $50.30.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3366470\" data-linked=\"Okta +1.5% as Needham steps to Buy\" data-tweet=\"$OKTA - Okta +1.5% as Needham steps to Buy https://seekingalpha.com/news/3366470-oktaplus-1_5-needham-steps-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3366470-oktaplus-1_5-needham-steps-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366465\" data-ts=\"1530098648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366465-endo-pharmaceuticals-up-2_6-on-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo Pharmaceuticals up 2.6% on Citi upgrade</a></h4><ul><li>No details are yet available but Citi joins the big move in Endo (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) with an upgrade to Buy from Hold.</li><li>Endo is&nbsp;<font color='green'>up 45%</font>&nbsp;over the past month, and&nbsp;<font color='green'>ahead another 2.6%</font>&nbsp;in premarket action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366465\" data-linked=\"Endo Pharmaceuticals up 2.6% on Citi upgrade\" data-tweet=\"$ENDP - Endo Pharmaceuticals up 2.6% on Citi upgrade https://seekingalpha.com/news/3366465-endo-pharmaceuticals-up-2_6-on-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3366465-endo-pharmaceuticals-up-2_6-on-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366464\" data-ts=\"1530098627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARA\" target=\"_blank\">CARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366464-cara-therapeutics-reports-positive-top-line-on-i-v-cr845\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cara Therapeutics reports positive top-line on I.V. CR845</a></h4><ul><li>           Cara Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a>) reports positive top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgery. </li><li> I.V. CR845 achieved statistical significance for the primary endpoint of pain relief over the 0 to 24-hour period post-surgery for combined surgeries at the 1.0 mcg/kg dose (p=0.032). </li><li> Treatment resulted in statistically significant reductions in the secondary endpoint of nausea and vomiting incidence at 24-hours for both the 0.5 and 1.0 mcg doses (p=0.006; p&lt;0.0001). </li><li> Cara will host a conference call at 8:30 AM to discuss the results with a webcast available <a href=\"http://ir.caratherapeutics.com/events\" target=\"_blank\">here.</a> </li><li> Cara shares were halted premarket and are expected to resume trading at 7:30 AM.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3366464\" data-linked=\"Cara Therapeutics reports positive top-line on I.V. CR845\" data-tweet=\"$CARA - Cara Therapeutics reports positive top-line on I.V. CR845 https://seekingalpha.com/news/3366464-cara-therapeutics-reports-positive-top-line-on-i-v-cr845?source=tweet\" data-url=\"https://seekingalpha.com/news/3366464-cara-therapeutics-reports-positive-top-line-on-i-v-cr845\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366462\" data-ts=\"1530098295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMMT\" target=\"_blank\">SMMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366462-summit-therapeutics-announces-trial-failure-shares-halted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Therapeutics announces trial failure; shares halted</a></h4><ul><li>The PhaseOut DMD did not meet its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy.</li><li>Summit (NASDAQ:<a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a>) is thus discontinuing development of ezutromid, and will be cutting costs. The company will now focus on development of its pipeline of new mechanism antibiotics, with lead candidate&nbsp;ridinilazole expected to enter Phase 3 trials&nbsp;for the treatment of C. difficile infection in Q1 2019.</li><li>A <a href=\"http://www.summitplc.com\" target=\"_blank\">conference call</a> is set for 8 ET.</li><li>Shares will resume trading at 7:30 ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3366462\" data-linked=\"Summit Therapeutics announces trial failure; shares halted\" data-tweet=\"$SMMT - Summit Therapeutics announces trial failure; shares halted https://seekingalpha.com/news/3366462-summit-therapeutics-announces-trial-failure-shares-halted?source=tweet\" data-url=\"https://seekingalpha.com/news/3366462-summit-therapeutics-announces-trial-failure-shares-halted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366459\" data-ts=\"1530097980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQXP\" target=\"_blank\">AQXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366459-aquinox-pharma-plunges-74-after-trial-failure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aquinox Pharma plunges 74% after trial failure</a></h4><ul><li>The Phase 3 Leadership 301 clinical trial for oral rosiptor (AQX-1125) for the treatment of&nbsp;interstitial cystitis/bladder pain syndrome (IC/BPS) failed to meet its primary endpoint.</li><li>Further development activities for rosiptor will be halted.</li><li><a href='https://seekingalpha.com/symbol/AQXP' title='Aquinox Pharmaceuticals, Inc.'>AQXP</a>&nbsp;<font color='red'>-73.9%</font>&nbsp;premarket</li><li>Source: <a href=\"https://seekingalpha.com/pr/17202790-aquinox-announces-topline-results-phase-3-leadership-301-clinical-trial-interstitial-cystitis\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3366459\" data-linked=\"Aquinox Pharma plunges 74% after trial failure\" data-tweet=\"$AQXP $NLTX - Aquinox Pharma plunges 74% after trial failure https://seekingalpha.com/news/3366459-aquinox-pharma-plunges-74-after-trial-failure?source=tweet\" data-url=\"https://seekingalpha.com/news/3366459-aquinox-pharma-plunges-74-after-trial-failure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366449\" data-ts=\"1530096826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366449-conagra-foods-beat-estimates-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConAgra Foods beat estimates in Q4</a></h4><ul><li>ConAgra Foods (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a>) reports organic net sales rose 2% in <a href=\"https://seekingalpha.com/pr/17202793-conagra-brands-completes-third-year-transformation-strong-end-fiscal-2018\" target=\"_blank\">Q4</a>,&nbsp;driven by solid growth in both domestic retail segments..</li><li>Segment net sales:&nbsp;Grocery &amp; Snacks: $803M (+7.1%);&nbsp;Refrigerated &amp; Frozen: $691M (+7.9%);&nbsp;International: $209M (+2%);&nbsp;Foodservice: $264M (-1.2%).</li><li>Adjusted gross margin rate improved12 bps to 29.2%.</li><li>During the quarter, the company repurchased ~3Mshares of its common stock for $107M.</li><li><strong>Q1 Guidance</strong>: Net sales: +2% to 2.5%; Adjusted operating marginrate: 14.1% to 14.4%; Adjusted diluted EPS: $0.46 to $0.</li><li><b>FY2019 Guidance</b>: Net sales: +0.5% to 1.5%; Organic net sales:&nbsp;+1% to +2%;&nbsp;Adjusted gross margin rate: 27% to 30%; Adjusted operating marginrate: 15% to 15.3%;&nbsp;Tax rate: 23% to 24%.</li><li>CAG&nbsp;<font color='red'>-2.96%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366445-conagra-brands-beats-0_06-beats-revenue\" target=\"_blank\">ConAgra Brands beats by $0.06, beats on revenue</a> (June 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3366449\" data-linked=\"ConAgra Foods beat estimates in Q4\" data-tweet=\"$CAG - ConAgra Foods beat estimates in Q4 https://seekingalpha.com/news/3366449-conagra-foods-beat-estimates-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3366449-conagra-foods-beat-estimates-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3366428\" data-ts=\"1530092551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3366428-astrazenecaplus-1_3-on-lynparza-success\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca +1.3% on Lynparza success</a></h4><ul><li>AstraZeneca's (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) oncology business got a <a href=\"https://www.reuters.com/article/us-astrazeneca-merck-co-cancer/astrazeneca-merck-eye-wider-cancer-drug-use-after-study-success-idUSKBN1JN0RF\" target=\"_blank\">boost</a> overnight as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.</li><li>The result should pave the way for expanded use of the medicine, which is being developed and marketed with Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) under a deal struck in 2017.</li><li>AZN <font color='green'>+1.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3366428\" data-linked=\"AstraZeneca +1.3% on Lynparza success\" data-tweet=\"$AZN $AZN $MRK - AstraZeneca +1.3% on Lynparza success https://seekingalpha.com/news/3366428-astrazenecaplus-1_3-on-lynparza-success?source=tweet\" data-url=\"https://seekingalpha.com/news/3366428-astrazenecaplus-1_3-on-lynparza-success\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}